PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30250148-9	2018	The findings of this study indicated that SLCO1B1 T521C was associated with a significantly higher risk of statin-induced myopathy, especially for simvastatin, rosuvastatin, and cerivastatin.	cerivastatin	178-190	solute carrier organic anion transporter family member 1B1	Homo sapiens	42-49
31633304-3	2019	Cerivastatin, the rate-limiting enzyme inhibitor of the mevalonate pathway, showed anti-cancer activity against ALK-TKI resistance in vitro/in vivo, accompanied by cytoplasmic retention and subsequent inactivation of transcriptional co-regulator YAP.	cerivastatin	0-12	ALK receptor tyrosine kinase	Homo sapiens	112-115
31633304-3	2019	Cerivastatin, the rate-limiting enzyme inhibitor of the mevalonate pathway, showed anti-cancer activity against ALK-TKI resistance in vitro/in vivo, accompanied by cytoplasmic retention and subsequent inactivation of transcriptional co-regulator YAP.	cerivastatin	0-12	Yes1 associated transcriptional regulator	Homo sapiens	246-249
31633304-4	2019	The marked induction of YAP-targeted oncogenes (EGFR, AXL, CYR61, and TGFbetaR2) in resistant cells was abolished by cerivastatin.	cerivastatin	117-129	Yes1 associated transcriptional regulator	Homo sapiens	24-27
31633304-4	2019	The marked induction of YAP-targeted oncogenes (EGFR, AXL, CYR61, and TGFbetaR2) in resistant cells was abolished by cerivastatin.	cerivastatin	117-129	epidermal growth factor receptor	Homo sapiens	48-52
31633304-4	2019	The marked induction of YAP-targeted oncogenes (EGFR, AXL, CYR61, and TGFbetaR2) in resistant cells was abolished by cerivastatin.	cerivastatin	117-129	AXL receptor tyrosine kinase	Homo sapiens	54-57
31633304-4	2019	The marked induction of YAP-targeted oncogenes (EGFR, AXL, CYR61, and TGFbetaR2) in resistant cells was abolished by cerivastatin.	cerivastatin	117-129	cellular communication network factor 1	Homo sapiens	59-64
31100067-2	2019	Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61).	cerivastatin	61-73	Yes1 associated transcriptional regulator	Homo sapiens	127-130
31100067-2	2019	Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61).	cerivastatin	61-73	Yes1 associated transcriptional regulator	Homo sapiens	201-204
31100067-2	2019	Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61).	cerivastatin	61-73	cellular communication network factor 2	Homo sapiens	226-257
31100067-2	2019	Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61).	cerivastatin	61-73	cellular communication network factor 2	Homo sapiens	259-263
31100067-2	2019	Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61).	cerivastatin	61-73	cellular communication network factor 1	Homo sapiens	269-304
31100067-2	2019	Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61).	cerivastatin	61-73	cellular communication network factor 1	Homo sapiens	306-311
28653847-5	2017	As interaction perpetrators with CYP2C8, glucuronides of gemfibrozil and clopidogrel showed marked clinical drug-drug interactions (e.g., with cerivastatin and repaglinide), which are more than expected from the parent drug.	cerivastatin	143-155	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	33-39
30112530-10	2018	Although addition of co-enzyme Q10 with cerivastatin inhibited degradation of sarcomeric alpha-actinin (SAA) in myoblasts, the contractile force still declined, suggesting that statin-induced myopathy was related to mevalonate pathway but the addition of co-enzyme Q10 was insufficient to overcome the effect of statins on the mevalonate pathway.	cerivastatin	40-52	actinin alpha 1	Homo sapiens	89-102
29728589-8	2018	Furthermore, interference of YAP nuclear translocation using the statin cerivastatin reverses the upregulation of Interleukin 6 (IL-6) and the pro-invasive effect of RA on MDA-MB-231 breast cancer cells and also decreases invasion and viability of MDA-MB-468 breast cancer cells.	cerivastatin	72-84	Yes1 associated transcriptional regulator	Homo sapiens	29-32
29728589-8	2018	Furthermore, interference of YAP nuclear translocation using the statin cerivastatin reverses the upregulation of Interleukin 6 (IL-6) and the pro-invasive effect of RA on MDA-MB-231 breast cancer cells and also decreases invasion and viability of MDA-MB-468 breast cancer cells.	cerivastatin	72-84	interleukin 6	Homo sapiens	114-127
29728589-8	2018	Furthermore, interference of YAP nuclear translocation using the statin cerivastatin reverses the upregulation of Interleukin 6 (IL-6) and the pro-invasive effect of RA on MDA-MB-231 breast cancer cells and also decreases invasion and viability of MDA-MB-468 breast cancer cells.	cerivastatin	72-84	interleukin 6	Homo sapiens	129-133
27631194-7	2016	Well-characterized haplotypes, *5 (RS4149056C) and *15 (RS4149056T), have been associated with a strikingly reduced uptake of multiple OATP1B1 substrates, including estrone-3-sulfate, estradiol-17beta-d-glucuronide, atorvastatin, cerivastatin, pravastatin, and rifampicin.	cerivastatin	230-242	solute carrier organic anion transporter family member 1B1	Homo sapiens	135-142
28438533-3	2017	miRNA expression profiling assay for cerivastatin (1 muM for 48 h)-treated RD cells showed more than 2-fold decrease in 26 miRNA expressions with miR-145 being downregulated prominently.	cerivastatin	37-49	microRNA 145	Homo sapiens	146-153
28438533-4	2017	When RD cells were treated with cerivastatin at 10 muM for 36 h, mitochondrial dysfunction was observed in 49.6% of the population without causing apoptosis, whereas 82% underwent apoptosis when treated at 10 muM for 48 h. In RD cells treated under the same condition (10 muM for 48 h), miR-145 expression and mRNA expressions of proapoptotic APAF1 and CASP10 genes, potential targets of miR-145, significantly decreased and increased, respectively.	cerivastatin	32-44	microRNA 145	Homo sapiens	287-294
28438533-4	2017	When RD cells were treated with cerivastatin at 10 muM for 36 h, mitochondrial dysfunction was observed in 49.6% of the population without causing apoptosis, whereas 82% underwent apoptosis when treated at 10 muM for 48 h. In RD cells treated under the same condition (10 muM for 48 h), miR-145 expression and mRNA expressions of proapoptotic APAF1 and CASP10 genes, potential targets of miR-145, significantly decreased and increased, respectively.	cerivastatin	32-44	apoptotic peptidase activating factor 1	Homo sapiens	343-348
28438533-4	2017	When RD cells were treated with cerivastatin at 10 muM for 36 h, mitochondrial dysfunction was observed in 49.6% of the population without causing apoptosis, whereas 82% underwent apoptosis when treated at 10 muM for 48 h. In RD cells treated under the same condition (10 muM for 48 h), miR-145 expression and mRNA expressions of proapoptotic APAF1 and CASP10 genes, potential targets of miR-145, significantly decreased and increased, respectively.	cerivastatin	32-44	caspase 10	Homo sapiens	353-359
28438533-4	2017	When RD cells were treated with cerivastatin at 10 muM for 36 h, mitochondrial dysfunction was observed in 49.6% of the population without causing apoptosis, whereas 82% underwent apoptosis when treated at 10 muM for 48 h. In RD cells treated under the same condition (10 muM for 48 h), miR-145 expression and mRNA expressions of proapoptotic APAF1 and CASP10 genes, potential targets of miR-145, significantly decreased and increased, respectively.	cerivastatin	32-44	microRNA 145	Homo sapiens	388-395
28438533-5	2017	Moreover, enforced expression of miR-145 reduced apoptotic cell population of cerivastatin-treated RD cells (10 muM for 36 h).	cerivastatin	78-90	microRNA 145	Homo sapiens	33-40
28438533-6	2017	Because miR-145 increased in extracellular medium from cerivastatin-treated RD cells, miR-145 was suggested to be secreted in response to statin-induced toxicity.	cerivastatin	55-67	microRNA 145	Homo sapiens	8-15
28438533-6	2017	Because miR-145 increased in extracellular medium from cerivastatin-treated RD cells, miR-145 was suggested to be secreted in response to statin-induced toxicity.	cerivastatin	55-67	microRNA 145	Homo sapiens	86-93
27175805-12	2016	Cerivastatin, but not pravastatin, protected Ras protein from trafficking to the cell membrane and significantly reduced expressions of SPP1 (p < 0.05) and SOX2 (p < 0.01).	cerivastatin	0-12	secreted phosphoprotein 1	Homo sapiens	136-140
27038110-7	2016	CONCLUSION: Anti-HMGCR autoantibody testing can be used to help differentiate whether a patient has self-limited myopathy due to cerivastatin or autoimmune statin-associated myopathy; these findings may apply to other statins as well.	cerivastatin	129-141	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	17-22
27175805-12	2016	Cerivastatin, but not pravastatin, protected Ras protein from trafficking to the cell membrane and significantly reduced expressions of SPP1 (p < 0.05) and SOX2 (p < 0.01).	cerivastatin	0-12	SRY-box transcription factor 2	Homo sapiens	159-163
26721703-3	2016	CYP2C8 substrate drugs include amodiaquine, cerivastatin, dasabuvir, enzalutamide, imatinib, loperamide, montelukast, paclitaxel, pioglitazone, repaglinide, and rosiglitazone, and the number is increasing.	cerivastatin	44-56	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
26556845-7	2015	Thus, the results showed that cerivastatin was a potent inhibitor of the inflammation genes MCP-1 and CCR2 through the induction of KLF2.	cerivastatin	30-42	C-C motif chemokine ligand 2	Homo sapiens	92-97
26556845-7	2015	Thus, the results showed that cerivastatin was a potent inhibitor of the inflammation genes MCP-1 and CCR2 through the induction of KLF2.	cerivastatin	30-42	C-C motif chemokine receptor 2	Homo sapiens	102-106
26556845-7	2015	Thus, the results showed that cerivastatin was a potent inhibitor of the inflammation genes MCP-1 and CCR2 through the induction of KLF2.	cerivastatin	30-42	Kruppel like factor 2	Homo sapiens	132-136
26556845-8	2015	The regulation of MCP-1, CCR2 and KLF2 by cerivastatin was isoprenoid pathway dependent.	cerivastatin	42-54	C-C motif chemokine ligand 2	Homo sapiens	18-23
26556845-8	2015	The regulation of MCP-1, CCR2 and KLF2 by cerivastatin was isoprenoid pathway dependent.	cerivastatin	42-54	C-C motif chemokine receptor 2	Homo sapiens	25-29
26556845-8	2015	The regulation of MCP-1, CCR2 and KLF2 by cerivastatin was isoprenoid pathway dependent.	cerivastatin	42-54	Kruppel like factor 2	Homo sapiens	34-38
25595597-6	2015	Other inhibitors of CYP2C8 (gemfibrozil, montelukast, clopidogrel glucuronide, repaglinide, and cerivastatin) also caused extensive inhibition of 3-hydroxydesloratadine formation (73%-100%).	cerivastatin	96-108	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	20-26
26412035-6	2015	UGT1A3 appeared to have the highest lactonization capacity with marked differences in statin conversion rates: pitavastatin >> atorvastatin > cerivastatin > lovastatin > rosuvastatin (simvastatin not converted).	cerivastatin	151-163	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	0-6
26556845-0	2015	Cerivastatin represses atherogenic gene expression through the induction of KLF2 via isoprenoid metabolic pathways.	cerivastatin	0-12	Kruppel like factor 2	Homo sapiens	76-80
26556845-3	2015	Cerivastatin significantly inhibited the two atherosclerotic genes, monocyte chemoattractant protein-1 (MCP-1) and C-C chemokine receptor type 2 (CCR2) at both the mRNA and protein levels, while the other statins did not.	cerivastatin	0-12	C-C motif chemokine ligand 2	Homo sapiens	68-102
26556845-3	2015	Cerivastatin significantly inhibited the two atherosclerotic genes, monocyte chemoattractant protein-1 (MCP-1) and C-C chemokine receptor type 2 (CCR2) at both the mRNA and protein levels, while the other statins did not.	cerivastatin	0-12	C-C motif chemokine ligand 2	Homo sapiens	104-109
26556845-3	2015	Cerivastatin significantly inhibited the two atherosclerotic genes, monocyte chemoattractant protein-1 (MCP-1) and C-C chemokine receptor type 2 (CCR2) at both the mRNA and protein levels, while the other statins did not.	cerivastatin	0-12	C-C motif chemokine receptor 2	Homo sapiens	115-144
26556845-3	2015	Cerivastatin significantly inhibited the two atherosclerotic genes, monocyte chemoattractant protein-1 (MCP-1) and C-C chemokine receptor type 2 (CCR2) at both the mRNA and protein levels, while the other statins did not.	cerivastatin	0-12	C-C motif chemokine receptor 2	Homo sapiens	146-150
26556845-4	2015	Accordingly, cerivastatin was also the most potent inducer of KLF2 transcription in the macrophages.	cerivastatin	13-25	Kruppel like factor 2	Homo sapiens	62-66
26556845-5	2015	An siRNA-induced reduction in KLF2 expression blocked the inhibition of MCP-1 and CCR2 by cerivastatin.	cerivastatin	90-102	Kruppel like factor 2	Homo sapiens	30-34
26556845-5	2015	An siRNA-induced reduction in KLF2 expression blocked the inhibition of MCP-1 and CCR2 by cerivastatin.	cerivastatin	90-102	C-C motif chemokine ligand 2	Homo sapiens	72-77
26556845-5	2015	An siRNA-induced reduction in KLF2 expression blocked the inhibition of MCP-1 and CCR2 by cerivastatin.	cerivastatin	90-102	C-C motif chemokine receptor 2	Homo sapiens	82-86
23652407-0	2013	OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.	cerivastatin	83-95	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
24971633-1	2014	Cerivastatin and repaglinide are substrates of cytochrome P450 (CYP)2C8, CYP3A4, and organic anion-transporting polypeptide (OATP)1B1.	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	47-71
24971633-1	2014	Cerivastatin and repaglinide are substrates of cytochrome P450 (CYP)2C8, CYP3A4, and organic anion-transporting polypeptide (OATP)1B1.	cerivastatin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-79
24971633-1	2014	Cerivastatin and repaglinide are substrates of cytochrome P450 (CYP)2C8, CYP3A4, and organic anion-transporting polypeptide (OATP)1B1.	cerivastatin	0-12	solute carrier organic anion transporter family member 1B1	Homo sapiens	85-133
23652407-2	2013	We investigated whether patients exhibiting rhabdomyolysis who were taking cerivastatin possess functional genetic variants in SLCO1B1 and whether they were on concomitant medications that inhibit OATP1B1, resulting in accumulation of cerivastatin.	cerivastatin	235-247	solute carrier organic anion transporter family member 1B1	Homo sapiens	197-204
23652407-5	2013	In-vitro functional analysis of SLCO1B1 nonsynonymous variants and haplotypes showed that the V174A, R57Q, and P155T variants, a novel frameshift insertion, OATP1B1*14 and OATP1B1*15 haplotype were associated with a significant reduction (P<0.001) in cerivastatin uptake (32, 18, 72, 3.4, 2.1 and 5.7% of reference, respectively).	cerivastatin	254-266	solute carrier organic anion transporter family member 1B1	Homo sapiens	32-39
23652407-5	2013	In-vitro functional analysis of SLCO1B1 nonsynonymous variants and haplotypes showed that the V174A, R57Q, and P155T variants, a novel frameshift insertion, OATP1B1*14 and OATP1B1*15 haplotype were associated with a significant reduction (P<0.001) in cerivastatin uptake (32, 18, 72, 3.4, 2.1 and 5.7% of reference, respectively).	cerivastatin	254-266	solute carrier organic anion transporter family member 1B1	Homo sapiens	157-164
23652407-6	2013	Furthermore, clopidogrel and seven other drugs were shown to inhibit OATP1B1-mediated uptake of cerivastatin.	cerivastatin	96-108	solute carrier organic anion transporter family member 1B1	Homo sapiens	69-76
23652407-7	2013	CONCLUSION: Reduced function of OATP1B1 related to genetic variation and drug-drug interactions likely contributed to cerivastatin-induced rhabdomyolysis.	cerivastatin	118-130	solute carrier organic anion transporter family member 1B1	Homo sapiens	32-39
23652407-8	2013	Although cerivastatin is no longer in clinical use, these findings may translate to related statins and other substrates of OATP1B1.	cerivastatin	9-21	solute carrier organic anion transporter family member 1B1	Homo sapiens	124-131
20739906-0	2010	Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	36-42
23092657-5	2012	In selenium-saturated cells, cerivastatin caused a largely indiscriminate suppression of selenoprotein biosynthesis and reduced the steady state-levels of glutathione peroxidase 1 (GPx1) and selenoprotein N (SelN).	cerivastatin	29-41	glutathione peroxidase 1	Homo sapiens	155-179
23092657-5	2012	In selenium-saturated cells, cerivastatin caused a largely indiscriminate suppression of selenoprotein biosynthesis and reduced the steady state-levels of glutathione peroxidase 1 (GPx1) and selenoprotein N (SelN).	cerivastatin	29-41	glutathione peroxidase 1	Homo sapiens	181-185
23092657-5	2012	In selenium-saturated cells, cerivastatin caused a largely indiscriminate suppression of selenoprotein biosynthesis and reduced the steady state-levels of glutathione peroxidase 1 (GPx1) and selenoprotein N (SelN).	cerivastatin	29-41	selenoprotein N	Homo sapiens	191-206
23092657-5	2012	In selenium-saturated cells, cerivastatin caused a largely indiscriminate suppression of selenoprotein biosynthesis and reduced the steady state-levels of glutathione peroxidase 1 (GPx1) and selenoprotein N (SelN).	cerivastatin	29-41	selenoprotein N	Homo sapiens	208-212
22365145-8	2012	Upon activation of alpha-adrenergic signalling - although ROS formation was not influenced by cerivastatin - TGFbeta expression decreased.	cerivastatin	94-106	transforming growth factor beta 1	Homo sapiens	109-116
22365145-9	2012	Following beta stimulation, TGFbeta expression as well as rac and p38 MAP kinase activation were reduced after pre-treatment with cerivastatin.	cerivastatin	130-142	transforming growth factor beta 1	Homo sapiens	28-35
22365145-9	2012	Following beta stimulation, TGFbeta expression as well as rac and p38 MAP kinase activation were reduced after pre-treatment with cerivastatin.	cerivastatin	130-142	mitogen-activated protein kinase 14	Homo sapiens	66-69
21726541-3	2011	In this study, the contribution of the redox partners cytochrome P450 reductase (CPR) and cytochrome b5 to the substrate dependent activity of CYP2C8.3 (R139K, K399R) was investigated in human liver microsomes (HLMs) and Escherichia coli expressed recombinant CYP2C8 proteins using amodiaquine, paclitaxel, rosiglitazone and cerivastatin as probe substrates.	cerivastatin	325-337	cytochrome p450 oxidoreductase	Homo sapiens	54-79
21726541-3	2011	In this study, the contribution of the redox partners cytochrome P450 reductase (CPR) and cytochrome b5 to the substrate dependent activity of CYP2C8.3 (R139K, K399R) was investigated in human liver microsomes (HLMs) and Escherichia coli expressed recombinant CYP2C8 proteins using amodiaquine, paclitaxel, rosiglitazone and cerivastatin as probe substrates.	cerivastatin	325-337	cytochrome p450 oxidoreductase	Homo sapiens	81-84
21726541-3	2011	In this study, the contribution of the redox partners cytochrome P450 reductase (CPR) and cytochrome b5 to the substrate dependent activity of CYP2C8.3 (R139K, K399R) was investigated in human liver microsomes (HLMs) and Escherichia coli expressed recombinant CYP2C8 proteins using amodiaquine, paclitaxel, rosiglitazone and cerivastatin as probe substrates.	cerivastatin	325-337	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	143-149
21710988-9	2011	At pH 6.0, OATP2B1-mediated transport of atorvastatin and cerivastatin was not inhibitable, while rosuvastatin transport was inhibited by E-3-S, rifamycin SV and cyclosporine with IC(50) values of 19.7 +- 3.3 muM, 0.53 +- 0.2 muM and 2.2 +- 0.4 muM, respectively.	cerivastatin	58-70	solute carrier organic anion transporter family member 2B1	Homo sapiens	11-18
21386754-7	2011	RESULTS: Permutation test results suggested an association between cerivastatin-associated rhabdomyolysis and variants in SLCO1B1 (P=0.002), but not variants in CYP2C8 (P=0.073) or UGTs (P=0.523).	cerivastatin	67-79	solute carrier organic anion transporter family member 1B1	Homo sapiens	122-129
20739906-3	2010	However, the effect of CYP2C8 genetic variation on cerivastatin metabolism has not been fully elucidated.	cerivastatin	51-63	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	23-29
20739906-4	2010	METHODS: In this study, patients (n=126) with confirmed cases of rhabdomyolysis after cerivastatin administration had their CYP2C8 gene resequenced and the metabolism of cerivastatin by the discovered CYP2C8 variants was assessed in proteins expressed in Escherichia coli.	cerivastatin	170-182	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	201-207
20739906-8	2010	Heterologously expressed CYP2C8.3 and CYP2C8.4 displayed an increase in cerivastatin metabolic clearance of up to six-fold compared with the wild-type enzyme.	cerivastatin	72-84	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	25-31
20739906-8	2010	Heterologously expressed CYP2C8.3 and CYP2C8.4 displayed an increase in cerivastatin metabolic clearance of up to six-fold compared with the wild-type enzyme.	cerivastatin	72-84	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	38-44
20739906-9	2010	Similarly, an independent sample of microsomes from human livers carrying the CYP2C8*3 and CYP2C8*4 alleles exhibited a 2-fold to 14-fold increase in normalized cerivastatin intrinsic clearance, compared with microsomes from livers carrying only the wild type allele.	cerivastatin	161-173	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	78-84
20739906-9	2010	Similarly, an independent sample of microsomes from human livers carrying the CYP2C8*3 and CYP2C8*4 alleles exhibited a 2-fold to 14-fold increase in normalized cerivastatin intrinsic clearance, compared with microsomes from livers carrying only the wild type allele.	cerivastatin	161-173	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	91-97
20739906-1	2010	OBJECTIVES: Cerivastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor withdrawn from the market because of serious adverse effects, is metabolized primarily by CYP2C8.	cerivastatin	12-24	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	28-75
20739906-10	2010	CONCLUSION: Gain or loss of catalytic function found in the CYP2C8 gene could certainly alter cerivastatin pharmacokinetics and may influence, at least in part, susceptibility to the development of myotoxicity.	cerivastatin	94-106	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	60-66
20739906-1	2010	OBJECTIVES: Cerivastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor withdrawn from the market because of serious adverse effects, is metabolized primarily by CYP2C8.	cerivastatin	12-24	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	176-182
20360620-3	2010	Incubation of HUVECs with fluvastatin, lovastatin or cerivastatin for 24 h caused an approximately 3-fold upregulation of eNOS expression that was associated with increased eNOS activity and accumulation of cGMP.	cerivastatin	53-65	nitric oxide synthase 3	Homo sapiens	122-126
20516252-7	2010	Although OATP siRNA decreased only 20 to 30% of the total uptake of cerivastatin into human hepatocytes, it caused a 50% reduction in cerivastatin metabolism, which was observed by monitoring the formation of the two major metabolites of cerivastatin.	cerivastatin	68-80	solute carrier organic anion transporter family member 1A2	Homo sapiens	9-13
20516252-7	2010	Although OATP siRNA decreased only 20 to 30% of the total uptake of cerivastatin into human hepatocytes, it caused a 50% reduction in cerivastatin metabolism, which was observed by monitoring the formation of the two major metabolites of cerivastatin.	cerivastatin	134-146	solute carrier organic anion transporter family member 1A2	Homo sapiens	9-13
20516252-7	2010	Although OATP siRNA decreased only 20 to 30% of the total uptake of cerivastatin into human hepatocytes, it caused a 50% reduction in cerivastatin metabolism, which was observed by monitoring the formation of the two major metabolites of cerivastatin.	cerivastatin	134-146	solute carrier organic anion transporter family member 1A2	Homo sapiens	9-13
20516252-8	2010	The results suggest that coadministration of a drug that is a hepatic OATP inhibitor could significantly alter the pharmacokinetic profile of cerivastatin in clinical studies.	cerivastatin	142-154	solute carrier organic anion transporter family member 1A2	Homo sapiens	70-74
20516252-9	2010	Further studies with this novel model demonstrated that OATP and cytochrome P450 have a synergistic effect on cerivastatin-gemfibrozil interactions.	cerivastatin	110-122	solute carrier organic anion transporter family member 1A2	Homo sapiens	56-60
20598021-8	2010	The lipophilic Cerivastatin (5 muM) reduced cellular cholesterol by 39% and abrogated apoB100 secretion by 3-fold.	cerivastatin	15-27	latexin	Homo sapiens	31-34
20598021-8	2010	The lipophilic Cerivastatin (5 muM) reduced cellular cholesterol by 39% and abrogated apoB100 secretion by 3-fold.	cerivastatin	15-27	apolipoprotein B	Homo sapiens	86-93
20360620-3	2010	Incubation of HUVECs with fluvastatin, lovastatin or cerivastatin for 24 h caused an approximately 3-fold upregulation of eNOS expression that was associated with increased eNOS activity and accumulation of cGMP.	cerivastatin	53-65	nitric oxide synthase 3	Homo sapiens	173-177
20214592-3	2009	In the structure of CYP2C8, the large active site cavity exhibits a trifurcated topology that approximates a T or Y shape, which is consistent with the finding that CYP2C8 can efficiently oxidize relatively large substrates such as paclitaxel and cerivastatin.	cerivastatin	247-259	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	20-26
20214592-3	2009	In the structure of CYP2C8, the large active site cavity exhibits a trifurcated topology that approximates a T or Y shape, which is consistent with the finding that CYP2C8 can efficiently oxidize relatively large substrates such as paclitaxel and cerivastatin.	cerivastatin	247-259	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	165-171
20214592-6	2009	CYP2C8 is a major catalyst in the metabolism of paclitaxel, amodiaquine, troglitazone, amiodarone, verapamil and ibuprofen, with a secondary role in the biotransformation of cerivastatin and fluvastatin.	cerivastatin	174-186	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
18283585-6	2008	RESULTS: We found that pretreatment with cerivastatin significantly abrogates the production of inflammatory cytokines TNF-alpha and MCP-1 by human monocytes in response to polymethylmethacrylate particle activation.	cerivastatin	41-53	tumor necrosis factor	Homo sapiens	119-128
19429419-5	2009	Sulforaphane significantly suppressed the expression of MDR1 and CYP3A mRNAs induced by atorvastatin lactone, lovastatin acid, and lovastatin lactone, comparable to the control level, and moderately inhibited that by cerivastatin acid, fluvastatin acid and simvastatin lactone.	cerivastatin	217-234	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
19429419-5	2009	Sulforaphane significantly suppressed the expression of MDR1 and CYP3A mRNAs induced by atorvastatin lactone, lovastatin acid, and lovastatin lactone, comparable to the control level, and moderately inhibited that by cerivastatin acid, fluvastatin acid and simvastatin lactone.	cerivastatin	217-234	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-70
18201784-5	2008	Furthermore, EC were incubated with pitavastatin or cerivastatin for 30 min, Western blot analysis showed that pitavastatin (0.1 microM) significantly upregulated the phosphorylation of eNOS and Akt about 1.4-fold or 1.3-fold compared with control, however, cerivastatin (0.1 microM) did not have any effects on them.	cerivastatin	52-64	AKT serine/threonine kinase 1	Homo sapiens	195-198
18426351-8	2008	RESULTS: Administration of cerivastatin improved significantly the survival rate of mice challenged with LPS (31% vs. 19% in the PBS group; p = 0.001), S. aureus (56% vs. 20% in PBS group; p = 0.01), or S. typhimurium (48% vs. 10% in PBS group; p = 0.03).	cerivastatin	27-39	toll-like receptor 4	Mus musculus	105-108
18426351-9	2008	Significantly reduced release of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 was evident in cerivastatin-treated mice after LPS challenge.	cerivastatin	136-148	tumor necrosis factor	Mus musculus	64-97
18426351-9	2008	Significantly reduced release of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 was evident in cerivastatin-treated mice after LPS challenge.	cerivastatin	136-148	interleukin 6	Mus musculus	102-120
18426351-9	2008	Significantly reduced release of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 was evident in cerivastatin-treated mice after LPS challenge.	cerivastatin	136-148	toll-like receptor 4	Mus musculus	168-171
18426351-10	2008	Cerivastatin-treated mice showed insignificant reductions in serum TNF-alpha and IL-6 concentrations after bacterial challenge.	cerivastatin	0-12	tumor necrosis factor	Mus musculus	67-76
18426351-10	2008	Cerivastatin-treated mice showed insignificant reductions in serum TNF-alpha and IL-6 concentrations after bacterial challenge.	cerivastatin	0-12	interleukin 6	Mus musculus	81-85
18426351-12	2008	CONCLUSIONS: Cerivastatin protects mice against LPS- and live bacteria-induced death, an effect associated with cerivastatin-attenuated pro-inflammatory cytokine production and enhanced bacterial clearance.	cerivastatin	13-25	toll-like receptor 4	Mus musculus	48-51
18426351-12	2008	CONCLUSIONS: Cerivastatin protects mice against LPS- and live bacteria-induced death, an effect associated with cerivastatin-attenuated pro-inflammatory cytokine production and enhanced bacterial clearance.	cerivastatin	112-124	toll-like receptor 4	Mus musculus	48-51
18283585-6	2008	RESULTS: We found that pretreatment with cerivastatin significantly abrogates the production of inflammatory cytokines TNF-alpha and MCP-1 by human monocytes in response to polymethylmethacrylate particle activation.	cerivastatin	41-53	C-C motif chemokine ligand 2	Homo sapiens	133-138
17553641-6	2007	Moreover, cerivastatin-induced apoptosis was associated with intracellular acidification and caspase-9 and -3/7 activation.	cerivastatin	10-22	caspase 9	Homo sapiens	93-109
19125197-8	2008	(4) Simvastatin, pravastatin, and cerivastatin markedly enhanced transcriptional activity in 293T cells cotransfected with acyl-coenzyme A oxidase promoter and PPARalpha/RXRalpha expression vectors.	cerivastatin	34-46	peroxisome proliferator activated receptor alpha	Homo sapiens	160-169
19125197-8	2008	(4) Simvastatin, pravastatin, and cerivastatin markedly enhanced transcriptional activity in 293T cells cotransfected with acyl-coenzyme A oxidase promoter and PPARalpha/RXRalpha expression vectors.	cerivastatin	34-46	retinoid X receptor alpha	Homo sapiens	170-178
17928646-2	2007	Based on the differences between hydrophobic and hydrophilic statins in their reduction of cardiac events, we analyzed the effects of rosuvastatin and cerivastatin on eNOS and inducible NO synthase (iNOS) expression and NOS activity in TNF-alpha-stimulated human umbilical vein endothelial cells (HUVEC).	cerivastatin	151-163	nitric oxide synthase 3	Homo sapiens	167-171
17928646-4	2007	Cerivastatin tended to a more pronounced effect on eNOS expression compared to rosuvastatin.	cerivastatin	0-12	nitric oxide synthase 3	Homo sapiens	51-55
17928646-7	2007	Rosuvastatin and cerivastatin reverse the detrimental effects of TNF-alpha-induced down-regulation in eNOS protein expression and increase NO synthase activity by inhibiting HMG-CoA reductase and subsequent blocking of isoprenoid synthesis.	cerivastatin	17-29	tumor necrosis factor	Homo sapiens	65-74
17928646-7	2007	Rosuvastatin and cerivastatin reverse the detrimental effects of TNF-alpha-induced down-regulation in eNOS protein expression and increase NO synthase activity by inhibiting HMG-CoA reductase and subsequent blocking of isoprenoid synthesis.	cerivastatin	17-29	nitric oxide synthase 3	Homo sapiens	102-106
17982704-5	2007	All statins tested (RSV, pravastatin [PRA], cerivastatin [CER], and simvastatin [SIM]) caused accumulation of unprenylated Rap-1A in rabbit osteoclast-like cells and J774 macrophages in vitro and inhibited osteoclast-mediated resorption.	cerivastatin	44-56	ras-related protein Rap-1A	Oryctolagus cuniculus	123-129
17982704-5	2007	All statins tested (RSV, pravastatin [PRA], cerivastatin [CER], and simvastatin [SIM]) caused accumulation of unprenylated Rap-1A in rabbit osteoclast-like cells and J774 macrophages in vitro and inhibited osteoclast-mediated resorption.	cerivastatin	58-61	ras-related protein Rap-1A	Oryctolagus cuniculus	123-129
17553641-7	2007	On the other hand, bicarbonate suppressed cerivastatin-induced pH alteration, caspase activation, morphological change and reduction of cell viability.	cerivastatin	42-54	caspase 9	Homo sapiens	78-85
17178262-8	2006	Furthermore, estrone-3-sulfate transport into OATP2B1-overexpressing Madin-Darby canine kidney II cells was inhibited by various drugs, including atorvastatin, simvastatin, cerivastatin, glyburide (INN, glibenclamide), and gemfibrozil, with the most pronounced effect being found for atorvastatin (inhibition constant, 0.7 +/- 0.4 micromol/L).	cerivastatin	173-185	solute carrier organic anion transporter family member 2B1	Homo sapiens	46-53
17701882-0	2007	The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.	cerivastatin	32-44	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-21
17701882-8	2007	After 12 weeks of treatment cerivastatin reduced cholesterol, apolipoprotein B, LDL cholesterol and the concentration of dense LDL.	cerivastatin	28-40	apolipoprotein B	Homo sapiens	62-78
17178259-6	2006	Cerivastatin is metabolized by CYP2C8 and CYP3A4, and fluvastatin is metabolized by CYP2C9.	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	31-37
17287218-3	2007	The aim of this study was to examine the anti-fibrotic effect of the HMG-CoA-reductase-inhibitor, cerivastatin, in COL4A3 knockout mice, an animal model of Alport syndrome with progressive renal fibrosis.	cerivastatin	98-110	collagen, type IV, alpha 3	Mus musculus	115-121
17287218-15	2007	CONCLUSION: Cerivastatin prolongs the lifespan of COL4A3 knockout mice, reduces proteinuria and delays uraemia.	cerivastatin	12-24	collagen, type IV, alpha 3	Mus musculus	50-56
17218607-9	2007	A decrease (35%) in HCR expression was also detected in femoral arteries from mice following voluntary exercise, and the bradykinin-induced vasodilatation of the mouse hindlimb was attenuated by both exercise and the HCR inhibitor cerivastatin.	cerivastatin	231-243	eukaryotic translation initiation factor 2 alpha kinase 1	Mus musculus	20-23
17218607-9	2007	A decrease (35%) in HCR expression was also detected in femoral arteries from mice following voluntary exercise, and the bradykinin-induced vasodilatation of the mouse hindlimb was attenuated by both exercise and the HCR inhibitor cerivastatin.	cerivastatin	231-243	eukaryotic translation initiation factor 2 alpha kinase 1	Mus musculus	217-220
16529752-0	2007	Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells.	cerivastatin	0-12	intercellular adhesion molecule 1	Homo sapiens	60-66
16529752-4	2007	The aim of this study was the comparison of cerivastatin and simvastatin-mediated effects on inflammation-induced ICAM-1 and VCAM-1 expression in human umbilical venous endothelial cells (HUVEC).	cerivastatin	44-56	intercellular adhesion molecule 1	Homo sapiens	114-120
16529752-4	2007	The aim of this study was the comparison of cerivastatin and simvastatin-mediated effects on inflammation-induced ICAM-1 and VCAM-1 expression in human umbilical venous endothelial cells (HUVEC).	cerivastatin	44-56	vascular cell adhesion molecule 1	Homo sapiens	125-131
16529752-6	2007	Co-incubation with cerivastatin, but not simvastatin reduced TNF-alpha-induced up-regulation of ICAM-1 surface expression whereas both statins reduced VCAM-1 surface expression; all reductions in surface expression correlated with an increase in the soluble forms of ICAM-1 and VCAM-1 in cell culture supernatants.	cerivastatin	19-31	tumor necrosis factor	Homo sapiens	61-70
16529752-6	2007	Co-incubation with cerivastatin, but not simvastatin reduced TNF-alpha-induced up-regulation of ICAM-1 surface expression whereas both statins reduced VCAM-1 surface expression; all reductions in surface expression correlated with an increase in the soluble forms of ICAM-1 and VCAM-1 in cell culture supernatants.	cerivastatin	19-31	intercellular adhesion molecule 1	Homo sapiens	96-102
16529752-6	2007	Co-incubation with cerivastatin, but not simvastatin reduced TNF-alpha-induced up-regulation of ICAM-1 surface expression whereas both statins reduced VCAM-1 surface expression; all reductions in surface expression correlated with an increase in the soluble forms of ICAM-1 and VCAM-1 in cell culture supernatants.	cerivastatin	19-31	intercellular adhesion molecule 1	Homo sapiens	267-273
16529752-6	2007	Co-incubation with cerivastatin, but not simvastatin reduced TNF-alpha-induced up-regulation of ICAM-1 surface expression whereas both statins reduced VCAM-1 surface expression; all reductions in surface expression correlated with an increase in the soluble forms of ICAM-1 and VCAM-1 in cell culture supernatants.	cerivastatin	19-31	vascular cell adhesion molecule 1	Homo sapiens	278-284
16529752-11	2007	We conclude that cerivastatin and simvastatin reduce TNF-alpha-induced up-regulation of ICAM-1 and VCAM-1 surface expression via increased protein shedding mediated by HMG-CoA reductase inhibition and subsequent isoprenoid depletion.	cerivastatin	17-29	tumor necrosis factor	Homo sapiens	53-62
16529752-11	2007	We conclude that cerivastatin and simvastatin reduce TNF-alpha-induced up-regulation of ICAM-1 and VCAM-1 surface expression via increased protein shedding mediated by HMG-CoA reductase inhibition and subsequent isoprenoid depletion.	cerivastatin	17-29	intercellular adhesion molecule 1	Homo sapiens	88-94
16529752-11	2007	We conclude that cerivastatin and simvastatin reduce TNF-alpha-induced up-regulation of ICAM-1 and VCAM-1 surface expression via increased protein shedding mediated by HMG-CoA reductase inhibition and subsequent isoprenoid depletion.	cerivastatin	17-29	vascular cell adhesion molecule 1	Homo sapiens	99-105
17184493-9	2006	Macrophage inflammatory protein-1alpha protein in THP-1 monocytes was reduced from 377 to 299 and 305 pg/mL by 0.1 micro mol/L simvastatin and 0.01 micro mol/L cerivastatin, respectively.	cerivastatin	160-172	C-C motif chemokine ligand 3	Homo sapiens	0-38
17184493-9	2006	Macrophage inflammatory protein-1alpha protein in THP-1 monocytes was reduced from 377 to 299 and 305 pg/mL by 0.1 micro mol/L simvastatin and 0.01 micro mol/L cerivastatin, respectively.	cerivastatin	160-172	GLI family zinc finger 2	Homo sapiens	50-55
17178259-6	2006	Cerivastatin is metabolized by CYP2C8 and CYP3A4, and fluvastatin is metabolized by CYP2C9.	cerivastatin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
16740997-3	2006	In the present study, we examined the effects of pitavastatin, pravastatin, atorvastatin, and cerivastatin on endothelin (ET)-1 production in cultured porcine aortic endothelial cells (PAECs).	cerivastatin	94-106	endothelin 1	Homo sapiens	110-127
17046548-0	2006	Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.	cerivastatin	123-135	tumor necrosis factor	Homo sapiens	0-27
17046548-0	2006	Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.	cerivastatin	123-135	serpin family E member 1	Homo sapiens	50-83
17046548-6	2006	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin inhibited TNF-alpha-induced PAI-1 production by 59%, which was reversed by coincubation with mevalonic acid.	cerivastatin	62-74	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-51
17046548-6	2006	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin inhibited TNF-alpha-induced PAI-1 production by 59%, which was reversed by coincubation with mevalonic acid.	cerivastatin	62-74	tumor necrosis factor	Homo sapiens	85-94
17046548-6	2006	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin inhibited TNF-alpha-induced PAI-1 production by 59%, which was reversed by coincubation with mevalonic acid.	cerivastatin	62-74	serpin family E member 1	Homo sapiens	103-108
16714062-7	2006	Cerivastatin is subjected to 2 metabolic pathways mediated by CYP2C8 and 3A4.	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	62-68
16740997-4	2006	Treatment with cerivastatin but not pitavastatin, pravastatin, or atorvastatin decreased basal and TNF-alpha-stimulated ET-1 release from PAECs in a dose-dependent manner (1-10 microM).	cerivastatin	15-27	tumor necrosis factor	Homo sapiens	99-108
16740997-4	2006	Treatment with cerivastatin but not pitavastatin, pravastatin, or atorvastatin decreased basal and TNF-alpha-stimulated ET-1 release from PAECs in a dose-dependent manner (1-10 microM).	cerivastatin	15-27	endothelin 1	Homo sapiens	120-124
16740997-5	2006	Northern blot analysis showed that cerivastatin markedly suppressed prepro ET-1 mRNA expression in both conditions.	cerivastatin	35-47	endothelin 1	Homo sapiens	75-79
16740997-6	2006	In addition, these inhibitory effects of cerivastatin on ET-1 release and prepro ET-1 mRNA expression were completely abolished by simultaneous treatment with 200 microM mevalonate.	cerivastatin	41-53	endothelin 1	Homo sapiens	57-61
16740997-6	2006	In addition, these inhibitory effects of cerivastatin on ET-1 release and prepro ET-1 mRNA expression were completely abolished by simultaneous treatment with 200 microM mevalonate.	cerivastatin	41-53	endothelin 1	Homo sapiens	81-85
16740997-8	2006	From these findings, it is most likely that cerivastatin suppresses ET-1 production, possibly through an increase in eNOS activity and the subsequent nitric oxide production in PAECs.	cerivastatin	44-56	endothelin 1	Homo sapiens	68-72
16740997-9	2006	These findings also suggest that cerivastatin may have beneficial effects on ET-1-related diseases.	cerivastatin	33-45	endothelin 1	Homo sapiens	77-81
16436135-6	2006	RESULTS: Preincubation of primary lung MCs with cerivastatin or atorvastatin (1-50 microM) for 24 h resulted in inhibition of anti-IgE-induced release of histamine.	cerivastatin	48-60	immunoglobulin heavy constant epsilon	Homo sapiens	131-134
16775505-11	2006	Cerivastatin (10 micromol/L) also reversed the down-regulation of eNOS by thrombin.	cerivastatin	0-12	coagulation factor II, thrombin	Homo sapiens	74-82
16775505-12	2006	Both simvastatin and cerivastatin-blocked thrombin-induced decrease in NOS activity.	cerivastatin	21-33	coagulation factor II, thrombin	Homo sapiens	42-50
16775505-14	2006	Simvastatin (10 micromol/L) and cerivastatin (10 micromol/L) significantly decreased thrombin-induced membrane translocation of Rho A.	cerivastatin	32-44	coagulation factor II, thrombin	Homo sapiens	85-93
16775505-14	2006	Simvastatin (10 micromol/L) and cerivastatin (10 micromol/L) significantly decreased thrombin-induced membrane translocation of Rho A.	cerivastatin	32-44	ras homolog family member A	Homo sapiens	128-133
16051251-4	2006	ECs were pre-incubated for 16 h with cerivastatin (10(-9) to 10(-7) M) or vehicle in the presence or absence of mevalonate, followed by stimulation with 20 ng/ml TNF-alpha.	cerivastatin	37-49	tumor necrosis factor	Homo sapiens	162-171
16259781-5	2005	Various statin-treated myoblasts were significantly stained with FITC-annexin V at 6 h, whereas they were not detected at 2 h. Moreover, immunoblot analysis indicated that when the cells were treated with cerivastatin (3 microM), membrane-associated Ras protein was activated and detached until 6 h, resulting in cell death through the consequent activation of caspase-8.	cerivastatin	205-217	annexin A5	Rattus norvegicus	70-79
16188392-9	2006	By blocking the protein prenylation, cerivastatin completely prevented the AGE-RAGE-elicited angiogenesis via suppression of vascular endothelial growth factor (VEGF).	cerivastatin	37-49	long intergenic non-protein coding RNA 914	Homo sapiens	79-83
16188392-9	2006	By blocking the protein prenylation, cerivastatin completely prevented the AGE-RAGE-elicited angiogenesis via suppression of vascular endothelial growth factor (VEGF).	cerivastatin	37-49	vascular endothelial growth factor A	Homo sapiens	125-159
16188392-9	2006	By blocking the protein prenylation, cerivastatin completely prevented the AGE-RAGE-elicited angiogenesis via suppression of vascular endothelial growth factor (VEGF).	cerivastatin	37-49	vascular endothelial growth factor A	Homo sapiens	161-165
16299161-9	2006	The results described have important implications for the mechanism of the clinical interaction reported between gemfibrozil and CYP2C8 substrates such as cerivastatin, repaglinide, rosiglitazone, and pioglitazone.	cerivastatin	155-167	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	129-135
16098957-10	2005	Cerivastatin significantly prevented stretch-induced membrane accumulation of Rho A.	cerivastatin	0-12	ras homolog family member A	Homo sapiens	78-83
16098957-13	2005	Stretch induced hyperphosphorylation of retinoblastoma protein (pRb), which was prevented by cerivastatin and the Rho kinase inhibitors.	cerivastatin	93-105	RB transcriptional corepressor 1	Homo sapiens	64-67
16259781-5	2005	Various statin-treated myoblasts were significantly stained with FITC-annexin V at 6 h, whereas they were not detected at 2 h. Moreover, immunoblot analysis indicated that when the cells were treated with cerivastatin (3 microM), membrane-associated Ras protein was activated and detached until 6 h, resulting in cell death through the consequent activation of caspase-8.	cerivastatin	205-217	caspase 8	Rattus norvegicus	361-370
15705602-4	2005	Cerivastatin promptly activated the cell death even in doxorubicin resistant cell lines such as MCC-2, whereas pravastatin, a hydrophilic compound, failed to induce any effect on either proliferation or apoptosis.	cerivastatin	0-12	USH1 protein network component harmonin binding protein 1	Homo sapiens	96-101
15901796-8	2005	Several statins inhibited the hBSEP- and rBsep-mediated uptake of TCA; however, the specific uptake of other statins (cerivastatin, fluvastatin, and pitavastatin) by hBSEP and rBSEP was not detected.	cerivastatin	118-130	ATP binding cassette subfamily B member 11	Homo sapiens	166-171
15802384-5	2005	Among them, HMG-CoA reductase inhibitors (cerivastatin, simvastatin, fluvastatin, and atorvastatin) enhanced the hCAR-mediated transcriptional activation of phenobarbital-responsive enhancer module reporter gene by up to 3-fold.	cerivastatin	42-54	CXADR Ig-like cell adhesion molecule	Homo sapiens	113-117
15802384-9	2005	Cerivastatin, simvastatin, fluvastatin, and atorvastatin induced CYP2B6 mRNA in stable hCAR-expressed FLC7 cells but not in original FLC7 cells.	cerivastatin	0-12	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	65-71
15802384-9	2005	Cerivastatin, simvastatin, fluvastatin, and atorvastatin induced CYP2B6 mRNA in stable hCAR-expressed FLC7 cells but not in original FLC7 cells.	cerivastatin	0-12	CXADR Ig-like cell adhesion molecule	Homo sapiens	87-91
15802384-11	2005	HMG-CoA reductase inhibitors such as cerivastatin would be useful to study for elucidating molecular and cellular mechanisms of hCAR.	cerivastatin	37-49	CXADR Ig-like cell adhesion molecule	Homo sapiens	128-132
15853752-6	2005	With the PAR-1 activating peptide SSFLRNP, we found that either cerivastatin or atorvastatin mitigated platelet stimulation in a time- and dose-dependent manner, as predicted if a statin-mediated Rho pathway is required.	cerivastatin	64-76	coagulation factor II thrombin receptor	Homo sapiens	9-14
15811174-7	2005	Cerivastatin is catabolized by cytochrome P450, 3A4 and 2C8 to M-1, and by 2C8 to M-23.	cerivastatin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-59
15772528-9	2005	Cerivastatin significantly dose-dependently inhibited both ex vivo platelet P-selectin expression, a marker of platelet activation, and platelet aggregation.	cerivastatin	0-12	selectin P	Rattus norvegicus	76-86
15811174-10	2005	These results suggest that the slowed clearance of cerivastatin in this patient might have been compounded by cytochrome P450, 2C8 dysfunction.	cerivastatin	51-63	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	110-130
15801991-2	2005	The purpose of this study was to determine whether a more potent statin (cerivastatin) would further affect CRP, whether a relation ship between CRP and BChE existed, and if there were any relationships between CRP or BChE and lipids.	cerivastatin	73-85	C-reactive protein	Homo sapiens	108-111
15801991-15	2005	CONCLUSION: Median CRP remained stable with pravastatin and cerivastatin use, although TC and LDL decreased.	cerivastatin	60-72	C-reactive protein	Homo sapiens	19-22
16020911-4	2005	In both cell lines, the statins (atorvastatin, cerivastatin and pitavastatin) induced the expression of four genes, which relate to cholesterol metabolism, namely, HMG-CoA synthase 1, HMG-CoA reductase, farnesyl diphosphate synthase and isopentenyl-diphosphate delta isomerase.	cerivastatin	47-59	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	184-201
16020911-4	2005	In both cell lines, the statins (atorvastatin, cerivastatin and pitavastatin) induced the expression of four genes, which relate to cholesterol metabolism, namely, HMG-CoA synthase 1, HMG-CoA reductase, farnesyl diphosphate synthase and isopentenyl-diphosphate delta isomerase.	cerivastatin	47-59	farnesyl diphosphate synthase	Homo sapiens	203-232
15389884-3	2004	Cerivastatin and atorvastatin dose-dependently inhibited in vitro calcification of human vascular smooth muscle cells (HVSMCs) induced by the following inflammatory mediators (IM): interferon-gamma, 1alpha,25-dihydroxyvitamin D3, tumor necrosis factor-alpha, and oncostatin M.	cerivastatin	0-12	interferon gamma	Homo sapiens	181-257
15601807-1	2005	Cytochrome P450 2C8 is involved in the metabolism of drugs such as paclitaxel, repaglinide, rosiglitazone, and cerivastatin, among others.	cerivastatin	111-123	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-19
15389884-3	2004	Cerivastatin and atorvastatin dose-dependently inhibited in vitro calcification of human vascular smooth muscle cells (HVSMCs) induced by the following inflammatory mediators (IM): interferon-gamma, 1alpha,25-dihydroxyvitamin D3, tumor necrosis factor-alpha, and oncostatin M.	cerivastatin	0-12	oncostatin M	Homo sapiens	263-275
15389884-5	2004	Mevalonate and geranylgeranylpyrophosphate reversed the inhibitory effect of cerivastatin on ALP expression in HVSMCs, while farnesylpyrophosphate showed no effect on the ALP activities inhibited by this drug, suggesting that inhibition of Rho and its downstream target, Rho kinase may mediate the inhibitory effect of cerivastatin.	cerivastatin	77-89	alkaline phosphatase, placental	Homo sapiens	93-96
15389884-6	2004	Cerivastatin prevented RhoA activation in HVSMCs induced by the IM.	cerivastatin	0-12	ras homolog family member A	Homo sapiens	23-27
15543343-6	2004	Total TFPI decreased significantly after cerivastatin (p = 0.002), but not after fenofibrate.	cerivastatin	41-53	tissue factor pathway inhibitor	Homo sapiens	6-10
15543343-9	2004	Cerivastatin decreased serum CRP values by 49.5% (p = 0.001), and fenofibrate by 29.8% (p = 0.03).	cerivastatin	0-12	C-reactive protein	Homo sapiens	29-32
15504460-4	2004	Compound A (a lactone) and Cerivastatin (an open acid) induced apoptosis, as measured by TUNEL and active caspase 3 staining, in a concentration- and time-dependent manner.	cerivastatin	27-39	caspase 3	Homo sapiens	106-115
15543343-14	2004	Both cerivastatin and fenofibrate reduced CRP levels, the decrease being significantly greater after cerivastatin.	cerivastatin	5-17	C-reactive protein	Homo sapiens	42-45
15543343-14	2004	Both cerivastatin and fenofibrate reduced CRP levels, the decrease being significantly greater after cerivastatin.	cerivastatin	101-113	C-reactive protein	Homo sapiens	42-45
15194707-0	2004	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.	cerivastatin	167-179	solute carrier organic anion transporter family member 1B1	Homo sapiens	44-84
15194707-0	2004	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.	cerivastatin	167-179	solute carrier organic anion transporter family member 1B1	Homo sapiens	86-91
15194707-0	2004	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.	cerivastatin	167-179	solute carrier organic anion transporter family member 1B1	Homo sapiens	92-99
15194707-0	2004	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.	cerivastatin	167-179	solute carrier organic anion transporter family member 1B1	Homo sapiens	100-107
15194707-0	2004	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.	cerivastatin	264-276	solute carrier organic anion transporter family member 1B1	Homo sapiens	44-84
15194707-0	2004	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.	cerivastatin	264-276	solute carrier organic anion transporter family member 1B1	Homo sapiens	86-91
15194707-0	2004	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.	cerivastatin	264-276	solute carrier organic anion transporter family member 1B1	Homo sapiens	92-99
15194707-0	2004	Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.	cerivastatin	264-276	solute carrier organic anion transporter family member 1B1	Homo sapiens	100-107
15247258-5	2004	IGF-I- and insulin-induced proliferation was significantly reduced by all statins tested, although cerivastatin (10 nm) had the greatest effect (p < 0.005).	cerivastatin	99-111	insulin-like growth factor 1	Mus musculus	0-5
15322734-5	2004	In addition, the hypothesis that gemfibrozil-mediated inhibition of P-glycoprotein contributes to the interaction between gemfibrozil and cerivastatin was tested in Caco-2 cells.	cerivastatin	138-150	ATP binding cassette subfamily B member 1	Homo sapiens	68-82
15302783-7	2004	Finally, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin restored the impaired neovascularization in kl/kl mice, accompanied by an increase in c-Kit+CD31+ cells in bone marrow and peripheral blood, and enhanced angiogenesis in the aortic-ring culture.	cerivastatin	71-83	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	13-60
15302783-7	2004	Finally, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin restored the impaired neovascularization in kl/kl mice, accompanied by an increase in c-Kit+CD31+ cells in bone marrow and peripheral blood, and enhanced angiogenesis in the aortic-ring culture.	cerivastatin	71-83	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	170-175
15302783-7	2004	Finally, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin restored the impaired neovascularization in kl/kl mice, accompanied by an increase in c-Kit+CD31+ cells in bone marrow and peripheral blood, and enhanced angiogenesis in the aortic-ring culture.	cerivastatin	71-83	platelet/endothelial cell adhesion molecule 1	Mus musculus	176-180
15322734-0	2004	Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.	cerivastatin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	38-52
15322734-6	2004	The apparent permeability coefficient (P(app)) value for the basal-to-apical transport of cerivastatin in Caco-2 and L-MDR1 cell monolayers was 2.4 times (P<0.001) and 3.8 times (P<0.001) as high as the apical-to-basal P(app) value respectively.	cerivastatin	90-102	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
15322734-0	2004	Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.	cerivastatin	20-32	ATP binding cassette subfamily B member 1	Homo sapiens	75-89
15322734-7	2004	The P-glycoprotein inhibitor PSC-833 (1 microM) inhibited the net basal-to-apical transport of cerivastatin in Caco-2 monolayers by 35% (P<0.01) and the MRP inhibitor MK-571 (10 microM) by 50% (P<0.01).	cerivastatin	95-107	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
15322734-0	2004	Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.	cerivastatin	20-32	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	121-126
15322734-11	2004	Collectively, these results indicate that cerivastatin is a P-glycoprotein substrate, although other transporters probably contribute to cerivastatin transport in humans.	cerivastatin	42-54	ATP binding cassette subfamily B member 1	Homo sapiens	60-74
15322734-1	2004	The aim of this study was to characterise the role of the efflux transporter P-glycoprotein in the disposition of cerivastatin.	cerivastatin	114-126	ATP binding cassette subfamily B member 1	Homo sapiens	77-91
14676196-5	2004	CYP2C8 is one of the principal hepatic drug-metabolizing enzymes that oxidizes therapeutic drugs such as taxol and cerivastatin and endobiotics such as retinoic acid and arachidonic acid.	cerivastatin	115-127	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
15262848-8	2004	Cerivastatin likewise inhibited the betaAR-stimulated activation of Rac1, decreased betaAR-stimulated apoptosis to 11+/-2%, and inhibited JNK activation, cytochrome C release, and caspase-3 activation.	cerivastatin	0-12	Rac family small GTPase 1	Rattus norvegicus	68-72
15262848-8	2004	Cerivastatin likewise inhibited the betaAR-stimulated activation of Rac1, decreased betaAR-stimulated apoptosis to 11+/-2%, and inhibited JNK activation, cytochrome C release, and caspase-3 activation.	cerivastatin	0-12	mitogen-activated protein kinase 8	Rattus norvegicus	138-141
15262848-8	2004	Cerivastatin likewise inhibited the betaAR-stimulated activation of Rac1, decreased betaAR-stimulated apoptosis to 11+/-2%, and inhibited JNK activation, cytochrome C release, and caspase-3 activation.	cerivastatin	0-12	caspase 3	Rattus norvegicus	180-189
15262848-10	2004	Cerivastatin inhibits betaAR-stimulated activation of Rac1 and thereby inhibits JNK-dependent activation of the mitochondrial death pathway and apoptosis.	cerivastatin	0-12	Rac family small GTPase 1	Rattus norvegicus	54-58
15262848-10	2004	Cerivastatin inhibits betaAR-stimulated activation of Rac1 and thereby inhibits JNK-dependent activation of the mitochondrial death pathway and apoptosis.	cerivastatin	0-12	mitogen-activated protein kinase 8	Rattus norvegicus	80-83
15166180-7	2004	Cerivastatin, pitavastatin, and fluvastatin inhibited atherosclerotic lesion progression in apolipoprotein E-deficient mice, whereas they augmented blood flow recovery and capillary formation in ischemic hind limb.	cerivastatin	0-12	apolipoprotein E	Mus musculus	92-108
15156558-4	2004	Extracellular accumulation of proteins such as VEGF, OCN, collagenase-digestive proteins, and noncollagenous proteins was increased in the cells treated with 10(-7) M simvastatin, or 10(-8) M cerivastatin.	cerivastatin	192-204	vascular endothelial growth factor A	Mus musculus	47-51
15146374-2	2004	METHODS: We examined the effects of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin on lipids, lipoproteins, and apolipoproteins in 69 patients with elevated fasting glucose, impaired glucose tolerance, or type 2 diabetes, combined hyperlipoproteinemia and increased concentrations of dense LDL (apo B in LDL-5 plus LDL-6 > 25 mg/dl).	cerivastatin	98-110	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	40-87
15146374-5	2004	Cerivastatin signficantly lowered apolipoprotein B in all LDL subfractions (- 21 to - 28 %, p < 0.05).	cerivastatin	0-12	apolipoprotein B	Homo sapiens	34-50
15146374-9	2004	CONCLUSIONS: The HMG CoA reductase inhibitor cerivastatin lowers total and LDL cholesterol and the concentration of dense LDL in patients with elevated fasting glucose, impaired glucose tolerance or type 2 diabetes.	cerivastatin	45-57	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	17-34
15067336-9	2004	We also demonstrated that cerivastatin exerts growth inhibitory effect through induction of p21 cyclin-dependent kinase inhibitor and inhibition of cell cycle progression.	cerivastatin	26-38	H3 histone pseudogene 16	Homo sapiens	92-95
14757118-0	2004	Cerivastatin inhibits proliferation of interleukin-1 beta-induced rat mesangial cells by enhanced formation of nitric oxide.	cerivastatin	0-12	interleukin 1 beta	Rattus norvegicus	39-57
14757118-6	2004	Interleukin-1 beta-induced nitrite production was twofold increased by 0.05 microM cerivastatin, and this effect could be reversed by addition of 100 microM mevalonate.	cerivastatin	83-95	interleukin 1 beta	Rattus norvegicus	0-18
14757118-2	2004	We studied in rat mesangial cells whether the antiproliferative action of cerivastatin on mesangial cells may be mediated by mesangial nitric oxide (NO) formation due to the inducible NO synthase (iNOS) or by induction of cyclooxygenase-2.	cerivastatin	74-86	nitric oxide synthase 2	Rattus norvegicus	174-195
14757118-2	2004	We studied in rat mesangial cells whether the antiproliferative action of cerivastatin on mesangial cells may be mediated by mesangial nitric oxide (NO) formation due to the inducible NO synthase (iNOS) or by induction of cyclooxygenase-2.	cerivastatin	74-86	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	222-238
14757118-7	2004	iNOS mRNA levels increased sixfold (33% of maximum) in cerivastatin-treated mesangial cells as compared with vehicle-treated controls (3.5% of maximum).	cerivastatin	55-67	nitric oxide synthase 2	Rattus norvegicus	0-4
14757118-5	2004	Cerivastatin (0.0625 microM) significantly inhibited DNA synthesis in interleukin-1 beta-stimulated mesangial cells without altering cell viability.	cerivastatin	0-12	interleukin 1 beta	Rattus norvegicus	70-88
14757118-10	2004	The cyclooxygenase-2 inhibitor celecoxib did not alter DNA synthesis and iNOS or cyclooxygenase-2 expression, but blocked prostacyclin production in interleukin-1 beta and cerivastatin-treated mesangial cells.	cerivastatin	172-184	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	4-20
14757118-11	2004	In conclusion, cerivastatin increased cytokine-induced iNOS and cyclooxygenase-2 expression, thus constituting NO-regulated growth inhibition of mesangial cells.	cerivastatin	15-27	nitric oxide synthase 2	Rattus norvegicus	55-59
14761784-9	2004	The cerivastatin cooperated with a MEK1/MEK2 inhibitor PD98059 to induce apoptosis, which appeared to correlate with down-regulation of ERK activation (phospho-ERKs expression) induced by the combination.	cerivastatin	4-16	mitogen-activated protein kinase kinase 1	Homo sapiens	35-39
14757118-11	2004	In conclusion, cerivastatin increased cytokine-induced iNOS and cyclooxygenase-2 expression, thus constituting NO-regulated growth inhibition of mesangial cells.	cerivastatin	15-27	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	64-80
14761784-9	2004	The cerivastatin cooperated with a MEK1/MEK2 inhibitor PD98059 to induce apoptosis, which appeared to correlate with down-regulation of ERK activation (phospho-ERKs expression) induced by the combination.	cerivastatin	4-16	mitogen-activated protein kinase kinase 2	Homo sapiens	40-44
14761784-9	2004	The cerivastatin cooperated with a MEK1/MEK2 inhibitor PD98059 to induce apoptosis, which appeared to correlate with down-regulation of ERK activation (phospho-ERKs expression) induced by the combination.	cerivastatin	4-16	mitogen-activated protein kinase 1	Homo sapiens	136-139
14761784-9	2004	The cerivastatin cooperated with a MEK1/MEK2 inhibitor PD98059 to induce apoptosis, which appeared to correlate with down-regulation of ERK activation (phospho-ERKs expression) induced by the combination.	cerivastatin	4-16	mitogen-activated protein kinase 1	Homo sapiens	160-164
14761784-10	2004	CONCLUSION: Cerivastatin-induced blockade of ERK activation in ASM cells might result in growth inhibition including apoptosis, which might explain some aspects of the beneficial effects of cerivastatin on coronary artery disease.	cerivastatin	12-24	mitogen-activated protein kinase 1	Homo sapiens	45-48
14761784-10	2004	CONCLUSION: Cerivastatin-induced blockade of ERK activation in ASM cells might result in growth inhibition including apoptosis, which might explain some aspects of the beneficial effects of cerivastatin on coronary artery disease.	cerivastatin	190-202	mitogen-activated protein kinase 1	Homo sapiens	45-48
15365880-0	2004	A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.	cerivastatin	116-128	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	24-30
15365880-2	2004	CYP2C8 and CYP3A4 are the major enzymes responsible for the metabolism of cerivastatin, and a transporter, OATP2, contributes to uptake of cerivastatin to the liver.	cerivastatin	74-86	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
15365880-2	2004	CYP2C8 and CYP3A4 are the major enzymes responsible for the metabolism of cerivastatin, and a transporter, OATP2, contributes to uptake of cerivastatin to the liver.	cerivastatin	74-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
15365880-2	2004	CYP2C8 and CYP3A4 are the major enzymes responsible for the metabolism of cerivastatin, and a transporter, OATP2, contributes to uptake of cerivastatin to the liver.	cerivastatin	74-86	solute carrier organic anion transporter family member 1B1	Homo sapiens	107-112
15365880-2	2004	CYP2C8 and CYP3A4 are the major enzymes responsible for the metabolism of cerivastatin, and a transporter, OATP2, contributes to uptake of cerivastatin to the liver.	cerivastatin	139-151	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
15365880-2	2004	CYP2C8 and CYP3A4 are the major enzymes responsible for the metabolism of cerivastatin, and a transporter, OATP2, contributes to uptake of cerivastatin to the liver.	cerivastatin	139-151	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
15365880-2	2004	CYP2C8 and CYP3A4 are the major enzymes responsible for the metabolism of cerivastatin, and a transporter, OATP2, contributes to uptake of cerivastatin to the liver.	cerivastatin	139-151	solute carrier organic anion transporter family member 1B1	Homo sapiens	107-112
15365880-10	2004	To our knowledge, this is the first report showing that the adverse effect of cerivastatin might be caused by the genetic variant of CYP2C8.	cerivastatin	78-90	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	133-139
14522253-5	2003	Cerivastatin (an inhibitor of HMG-coA reductase) or mecamylamine (an inhibitor of nicotinic acetylcholine receptors) suppressed the effect of SHS to increase tumor size and capillary density.	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	30-47
14563711-3	2003	Here we demonstrated that the statins tested, ie, cerivastatin, simvastatin, lovastatin, and atorvastatin, promoted Th2 polarization through both inhibition of Th1 development and augmentation of Th2 development of CD4+ T cells primed in vitro with anti-CD3 antibody and splenic antigen-presenting cells.	cerivastatin	50-62	heart and neural crest derivatives expressed 2	Mus musculus	116-119
14563711-3	2003	Here we demonstrated that the statins tested, ie, cerivastatin, simvastatin, lovastatin, and atorvastatin, promoted Th2 polarization through both inhibition of Th1 development and augmentation of Th2 development of CD4+ T cells primed in vitro with anti-CD3 antibody and splenic antigen-presenting cells.	cerivastatin	50-62	negative elongation factor complex member C/D, Th1l	Mus musculus	160-163
14563711-3	2003	Here we demonstrated that the statins tested, ie, cerivastatin, simvastatin, lovastatin, and atorvastatin, promoted Th2 polarization through both inhibition of Th1 development and augmentation of Th2 development of CD4+ T cells primed in vitro with anti-CD3 antibody and splenic antigen-presenting cells.	cerivastatin	50-62	heart and neural crest derivatives expressed 2	Mus musculus	196-199
14563711-4	2003	Cerivastatin exerted most potent effect on modulation of Th1/Th2 development, and the effect was completely abrogated by an addition of mevalonate.	cerivastatin	0-12	negative elongation factor complex member C/D, Th1l	Mus musculus	57-60
14563711-4	2003	Cerivastatin exerted most potent effect on modulation of Th1/Th2 development, and the effect was completely abrogated by an addition of mevalonate.	cerivastatin	0-12	heart and neural crest derivatives expressed 2	Mus musculus	61-64
14563711-5	2003	Consistent with in vitro experiments, cerivastatin treatment decreased IFN-gamma production of lymph node cells from mice immunized with ovalbumin emulsified in complete Freund"s adjuvant, indicating that Th1 development is also suppressed in an in vivo proinflammatory environment.	cerivastatin	38-50	interferon gamma	Mus musculus	71-80
14563711-5	2003	Consistent with in vitro experiments, cerivastatin treatment decreased IFN-gamma production of lymph node cells from mice immunized with ovalbumin emulsified in complete Freund"s adjuvant, indicating that Th1 development is also suppressed in an in vivo proinflammatory environment.	cerivastatin	38-50	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	137-146
14563711-5	2003	Consistent with in vitro experiments, cerivastatin treatment decreased IFN-gamma production of lymph node cells from mice immunized with ovalbumin emulsified in complete Freund"s adjuvant, indicating that Th1 development is also suppressed in an in vivo proinflammatory environment.	cerivastatin	38-50	negative elongation factor complex member C/D, Th1l	Mus musculus	205-208
14563711-7	2003	The decrease of glomerular sclerosis by cerivastatin treatment was positively related to the suppression of interferon (IFN)-gamma-producing Th1 response in draining lymph node cells.	cerivastatin	40-52	interferon gamma	Mus musculus	108-130
14563711-7	2003	The decrease of glomerular sclerosis by cerivastatin treatment was positively related to the suppression of interferon (IFN)-gamma-producing Th1 response in draining lymph node cells.	cerivastatin	40-52	negative elongation factor complex member C/D, Th1l	Mus musculus	141-144
14583185-0	2003	Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activation.	cerivastatin	0-12	insulin	Homo sapiens	30-37
14583185-0	2003	Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activation.	cerivastatin	0-12	intercellular adhesion molecule 1	Homo sapiens	100-133
14583185-7	2003	RESULTS: Both the increased neutrophil-endothelial cell adhesion and ICAM-1 expression caused by high insulin (100 microU/ml) for 48 h were significantly attenuated by pretreatment with cerivastatin (0.01 microM), but not by fluvastatin (0.5 microM) or pravastatin (0.05 microM).	cerivastatin	186-198	intercellular adhesion molecule 1	Homo sapiens	69-75
14583185-7	2003	RESULTS: Both the increased neutrophil-endothelial cell adhesion and ICAM-1 expression caused by high insulin (100 microU/ml) for 48 h were significantly attenuated by pretreatment with cerivastatin (0.01 microM), but not by fluvastatin (0.5 microM) or pravastatin (0.05 microM).	cerivastatin	186-198	insulin	Homo sapiens	102-109
14583185-9	2003	In addition, cerivastatin attenuated both neutrophil-endothelial cell adhesion and endothelial ICAM-1 expression enhanced by a MAP kinase activator, anisomycin (1 microM) but not by a PKC activator, PMA (10 nM).	cerivastatin	13-25	intercellular adhesion molecule 1	Homo sapiens	95-101
14583185-10	2003	CONCLUSIONS: These results suggest that through inhibiting MAP kinase but not PKC activation therapy with cerivastatin would be promising strategy for inhibiting neutrophil-endothelial cell adhesion and endothelial ICAM-1 expression enhanced by high insulin, which is closely correlated with atherosclerosis.	cerivastatin	106-118	intercellular adhesion molecule 1	Homo sapiens	215-221
14583185-10	2003	CONCLUSIONS: These results suggest that through inhibiting MAP kinase but not PKC activation therapy with cerivastatin would be promising strategy for inhibiting neutrophil-endothelial cell adhesion and endothelial ICAM-1 expression enhanced by high insulin, which is closely correlated with atherosclerosis.	cerivastatin	106-118	insulin	Homo sapiens	250-257
14517172-9	2003	GAD scores decreased in low-dose (P<0.05) and high-dose (P<0.0001) cerivastatin groups compared with controls, with concomitant reduction in graft-infiltrating cells and significantly decreased intragraft RANTES and monocyte chemotactic protein-1 mRNA expression.	cerivastatin	73-85	chemokine (C-C motif) ligand 5	Mus musculus	211-217
14517172-9	2003	GAD scores decreased in low-dose (P<0.05) and high-dose (P<0.0001) cerivastatin groups compared with controls, with concomitant reduction in graft-infiltrating cells and significantly decreased intragraft RANTES and monocyte chemotactic protein-1 mRNA expression.	cerivastatin	73-85	chemokine (C-C motif) ligand 2	Mus musculus	222-252
14517172-10	2003	Cerivastatin, as well as other statins, also reduced RANTES and monocyte chemotactic protein-1 production in mouse endothelial cells stimulated with interferon-gamma and tumor necrosis factor-alpha in vitro.	cerivastatin	0-12	chemokine (C-C motif) ligand 5	Mus musculus	53-59
14517172-10	2003	Cerivastatin, as well as other statins, also reduced RANTES and monocyte chemotactic protein-1 production in mouse endothelial cells stimulated with interferon-gamma and tumor necrosis factor-alpha in vitro.	cerivastatin	0-12	chemokine (C-C motif) ligand 2	Mus musculus	64-94
14517172-10	2003	Cerivastatin, as well as other statins, also reduced RANTES and monocyte chemotactic protein-1 production in mouse endothelial cells stimulated with interferon-gamma and tumor necrosis factor-alpha in vitro.	cerivastatin	0-12	interferon gamma	Mus musculus	149-197
14612203-4	2003	Lovastatin, simvastatin, atorvastatin, fluvastatin and cerivastatin, which are hydrophobic statins, markedly reduced cell viability associated with DNA fragmentation, DNA laddering and activation of caspase-3, suggesting apoptotic cell death.	cerivastatin	55-67	caspase 3	Rattus norvegicus	199-208
14556080-6	2003	HMG-CoA inhibition with cerivastatin-reduced VSMC proliferation and C5b-9-induced ERK1/2 activation.	cerivastatin	24-36	mitogen-activated protein kinase 3	Homo sapiens	82-88
14556080-7	2003	Cerivastatin also reduced the C5b-9-induced synthesis of the proinflammatory interleukin-6 (IL-6).	cerivastatin	0-12	interleukin 6	Homo sapiens	77-90
14556080-7	2003	Cerivastatin also reduced the C5b-9-induced synthesis of the proinflammatory interleukin-6 (IL-6).	cerivastatin	0-12	interleukin 6	Homo sapiens	92-96
14556080-8	2003	Furthermore, C5b-9 induced activation of the transcription factors activator protein- 1 (AP-1) and nuclear factor-kappaB (NF-kappaB), which could be inhibited by pretreatment of VSMCs with cerivastatin.	cerivastatin	189-201	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	67-87
14556080-8	2003	Furthermore, C5b-9 induced activation of the transcription factors activator protein- 1 (AP-1) and nuclear factor-kappaB (NF-kappaB), which could be inhibited by pretreatment of VSMCs with cerivastatin.	cerivastatin	189-201	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	89-93
14556080-10	2003	The present study in VSMCs shows that cerivastatin inhibits IL-6 synthesis and cell proliferation induced by the terminal complement complex C5b-9.	cerivastatin	38-50	interleukin 6	Homo sapiens	60-64
12923172-4	2003	When expressed in human embryonic kidney 293 cells, Oatp14 transports thyroxine (T4; prothyroid hormone) (Km = 0.18 mum), as well as amphipathic organic anions such as 17beta estradiol-d-17beta-glucuronide (Km = 10 mum), cerivastatin (Km = 1.3 mum), and troglitazone sulfate (Km = 0.76 mum).	cerivastatin	221-233	solute carrier organic anion transporter family member 1C1	Homo sapiens	52-58
12933532-0	2003	Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells.	cerivastatin	14-26	chemokine (C-C motif) ligand 2	Mus musculus	35-69
12933532-0	2003	Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells.	cerivastatin	14-26	coagulation factor III	Mus musculus	74-87
12933532-3	2003	METHODS AND RESULTS: The withdrawal of cerivastatin from pretreated vascular smooth muscle cells induced an increase in monocyte chemoattractant protein 1 (MCP-1) and tissue factor (TF) mRNA expression and enhanced MCP-1 secretion as well as cell surface TF activity.	cerivastatin	39-51	chemokine (C-C motif) ligand 2	Mus musculus	120-154
12933532-3	2003	METHODS AND RESULTS: The withdrawal of cerivastatin from pretreated vascular smooth muscle cells induced an increase in monocyte chemoattractant protein 1 (MCP-1) and tissue factor (TF) mRNA expression and enhanced MCP-1 secretion as well as cell surface TF activity.	cerivastatin	39-51	chemokine (C-C motif) ligand 2	Mus musculus	156-161
12933532-3	2003	METHODS AND RESULTS: The withdrawal of cerivastatin from pretreated vascular smooth muscle cells induced an increase in monocyte chemoattractant protein 1 (MCP-1) and tissue factor (TF) mRNA expression and enhanced MCP-1 secretion as well as cell surface TF activity.	cerivastatin	39-51	coagulation factor III	Mus musculus	167-180
12933532-3	2003	METHODS AND RESULTS: The withdrawal of cerivastatin from pretreated vascular smooth muscle cells induced an increase in monocyte chemoattractant protein 1 (MCP-1) and tissue factor (TF) mRNA expression and enhanced MCP-1 secretion as well as cell surface TF activity.	cerivastatin	39-51	coagulation factor III	Mus musculus	182-184
12933532-3	2003	METHODS AND RESULTS: The withdrawal of cerivastatin from pretreated vascular smooth muscle cells induced an increase in monocyte chemoattractant protein 1 (MCP-1) and tissue factor (TF) mRNA expression and enhanced MCP-1 secretion as well as cell surface TF activity.	cerivastatin	39-51	chemokine (C-C motif) ligand 2	Mus musculus	215-220
12933532-3	2003	METHODS AND RESULTS: The withdrawal of cerivastatin from pretreated vascular smooth muscle cells induced an increase in monocyte chemoattractant protein 1 (MCP-1) and tissue factor (TF) mRNA expression and enhanced MCP-1 secretion as well as cell surface TF activity.	cerivastatin	39-51	coagulation factor III	Mus musculus	255-257
14522253-6	2003	Cerivastatin reduced MCP-1 levels, whereas mecamylamine reduced VEGF levels and EPC.	cerivastatin	0-12	mast cell protease 1	Mus musculus	21-26
12960680-0	2003	The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium.	cerivastatin	32-44	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-21
12960680-1	2003	The aim of this study was to investigate whether the HMG-CoA reductase inhibitor cerivastatin alters the nitric oxide (NO) bioavailability of porcine aortic endothelial cell cultures and of native porcine coronary endothelium, after short-term (minutes) and long-term (24-hour) treatment with cerivastatin (electrochemical NO sensor).	cerivastatin	81-93	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	53-70
12960680-3	2003	Furthermore, the authors investigated whether cerivastatin modulates an angiotensin II (10 micromol/L; 4 hours) induced reactive oxygen species (ROS) release from intact vessels (lucigenin-enhanced chemiluminescence-assay).	cerivastatin	46-58	angiotensinogen	Homo sapiens	72-86
12960680-7	2003	However, cerivastatin induced a significant concentration-dependent inhibition of the angiotensin II-induced ROS release from native endothelial cells of porcine coronary arteries.	cerivastatin	9-21	angiotensinogen	Homo sapiens	86-100
12883330-3	2003	The authors compared the effect of 2 HMG-CoA reductase inhibitors, atorvastatin and cerivastatin, on the synthesis and secretion of apoE and apoC-I by THP-1 macrophages.	cerivastatin	84-96	apolipoprotein E	Homo sapiens	132-136
12953163-0	2003	HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes.	cerivastatin	28-40	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
12953163-0	2003	HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes.	cerivastatin	28-40	interleukin 6	Homo sapiens	50-63
12953163-3	2003	In the current study, we investigated the effect of the HMG-CoA reductase inhibitor, cerivastatin, on the production of IL-6 from cultured human adipocytes.	cerivastatin	85-97	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	56-73
12953163-3	2003	In the current study, we investigated the effect of the HMG-CoA reductase inhibitor, cerivastatin, on the production of IL-6 from cultured human adipocytes.	cerivastatin	85-97	interleukin 6	Homo sapiens	120-124
12953163-4	2003	Cerivastatin reduced both IL-6 mRNA and secretion in a dose- and time-dependent manner.	cerivastatin	0-12	interleukin 6	Homo sapiens	26-30
12953163-6	2003	This suggests the involvement of geranylgeranyl-modified intermediates in the effect of cerivastatin on IL-6.	cerivastatin	88-100	interleukin 6	Homo sapiens	104-108
12953163-7	2003	Moreover, cerivastatin induced an inactivation of the phosphorylation of the p65 subunit of NFkappaB which was prevented by GGPP.	cerivastatin	10-22	RELA proto-oncogene, NF-kB subunit	Homo sapiens	77-80
12953163-8	2003	Our data suggest that cerivastatin exerts an anti-inflammatory effect by down-regulating IL-6 levels in adipocytes, which seems to be mediated by reduced production of GGPP and interference with the NFkappaB pathway.	cerivastatin	22-34	interleukin 6	Homo sapiens	89-93
12883330-3	2003	The authors compared the effect of 2 HMG-CoA reductase inhibitors, atorvastatin and cerivastatin, on the synthesis and secretion of apoE and apoC-I by THP-1 macrophages.	cerivastatin	84-96	apolipoprotein C1	Homo sapiens	141-147
12883330-3	2003	The authors compared the effect of 2 HMG-CoA reductase inhibitors, atorvastatin and cerivastatin, on the synthesis and secretion of apoE and apoC-I by THP-1 macrophages.	cerivastatin	84-96	GLI family zinc finger 2	Homo sapiens	151-156
12883330-6	2003	Cerivastatin similarly reduced medium apoE (-20% at 1-micromol/L, P < 0.05) and cellular apoE mRNA (-31% at 1-micromol/L, P < 0.05), and significantly lowered cellular apoC-I mRNA (-15%, P < 0.05), but not apoC-I in the medium.	cerivastatin	0-12	apolipoprotein E	Homo sapiens	38-42
12883330-6	2003	Cerivastatin similarly reduced medium apoE (-20% at 1-micromol/L, P < 0.05) and cellular apoE mRNA (-31% at 1-micromol/L, P < 0.05), and significantly lowered cellular apoC-I mRNA (-15%, P < 0.05), but not apoC-I in the medium.	cerivastatin	0-12	apolipoprotein E	Homo sapiens	92-96
12883330-6	2003	Cerivastatin similarly reduced medium apoE (-20% at 1-micromol/L, P < 0.05) and cellular apoE mRNA (-31% at 1-micromol/L, P < 0.05), and significantly lowered cellular apoC-I mRNA (-15%, P < 0.05), but not apoC-I in the medium.	cerivastatin	0-12	apolipoprotein C1	Homo sapiens	174-180
12883330-6	2003	Cerivastatin similarly reduced medium apoE (-20% at 1-micromol/L, P < 0.05) and cellular apoE mRNA (-31% at 1-micromol/L, P < 0.05), and significantly lowered cellular apoC-I mRNA (-15%, P < 0.05), but not apoC-I in the medium.	cerivastatin	0-12	apolipoprotein C1	Homo sapiens	215-221
12883330-7	2003	In experiments with THP-1 macrophages loaded with cholesterol (ie, 24-hour incubation with acetyl-LDL), atorvastatin and cerivastatin (1-micromol/L) significantly (P < 0.05) reduced both medium apoE (-30% and -25%, respectively) and cellular apoE mRNA (-25% and -17%, respectively).	cerivastatin	121-133	GLI family zinc finger 2	Homo sapiens	20-25
12883330-7	2003	In experiments with THP-1 macrophages loaded with cholesterol (ie, 24-hour incubation with acetyl-LDL), atorvastatin and cerivastatin (1-micromol/L) significantly (P < 0.05) reduced both medium apoE (-30% and -25%, respectively) and cellular apoE mRNA (-25% and -17%, respectively).	cerivastatin	121-133	apolipoprotein E	Homo sapiens	197-201
12883330-7	2003	In experiments with THP-1 macrophages loaded with cholesterol (ie, 24-hour incubation with acetyl-LDL), atorvastatin and cerivastatin (1-micromol/L) significantly (P < 0.05) reduced both medium apoE (-30% and -25%, respectively) and cellular apoE mRNA (-25% and -17%, respectively).	cerivastatin	121-133	apolipoprotein E	Homo sapiens	245-249
12827036-5	2003	Western blot analysis showed that the extent of phosphorylation of Akt, an active form of Akt, was increased by cerivastatin while it was reduced by LY294002, suggesting an involvement of PI3 kinase/Akt-dependent activation of endothelial NOS.	cerivastatin	112-124	AKT serine/threonine kinase 1	Rattus norvegicus	67-70
12827036-5	2003	Western blot analysis showed that the extent of phosphorylation of Akt, an active form of Akt, was increased by cerivastatin while it was reduced by LY294002, suggesting an involvement of PI3 kinase/Akt-dependent activation of endothelial NOS.	cerivastatin	112-124	AKT serine/threonine kinase 1	Rattus norvegicus	90-93
12827036-5	2003	Western blot analysis showed that the extent of phosphorylation of Akt, an active form of Akt, was increased by cerivastatin while it was reduced by LY294002, suggesting an involvement of PI3 kinase/Akt-dependent activation of endothelial NOS.	cerivastatin	112-124	AKT serine/threonine kinase 1	Rattus norvegicus	90-93
12663370-5	2003	Cerivastatin (50 nmol/L) inhibited inducible MMP-1, -3, and -9 secretion from human SMC by 52+/-19%, 71+/-18%, and 73+/-17%, respectively (P<0.01, n=3).	cerivastatin	0-12	matrix metallopeptidase 1	Homo sapiens	45-62
12774163-8	2003	Cerivastatin treatment (1.0 mg/kg) inhibited the up-regulated expression of MCP-1 and TGF-beta mRNA (decreased to 48% and 34%, respectively) in diabetic SHR.	cerivastatin	0-12	mast cell protease 1-like 1	Rattus norvegicus	76-81
12774163-8	2003	Cerivastatin treatment (1.0 mg/kg) inhibited the up-regulated expression of MCP-1 and TGF-beta mRNA (decreased to 48% and 34%, respectively) in diabetic SHR.	cerivastatin	0-12	transforming growth factor, beta 1	Rattus norvegicus	86-94
12667961-10	2003	Fluvastatin and cerivastatin also reduced the activation of NF-kappaB by CRP.	cerivastatin	16-28	nuclear factor kappa B subunit 1	Homo sapiens	60-69
12667961-10	2003	Fluvastatin and cerivastatin also reduced the activation of NF-kappaB by CRP.	cerivastatin	16-28	C-reactive protein	Homo sapiens	73-76
12740486-3	2003	The inhibitory effect of cerivastatin on the PDGF-BB-induced activation of ERK1/2 was fully recovered by the addition of geranylgeranyl pyrophosphate (GGPP), but not farnesyl pyrophosphate (FPP).	cerivastatin	25-37	mitogen activated protein kinase 3	Rattus norvegicus	75-81
12841342-0	2003	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction.	cerivastatin	33-45	C-reactive protein	Homo sapiens	68-86
12841342-0	2003	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction.	cerivastatin	33-45	interleukin 6	Homo sapiens	88-101
12841342-0	2003	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction.	cerivastatin	33-45	C-X-C motif chemokine ligand 8	Homo sapiens	107-120
12841342-1	2003	The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later.	cerivastatin	62-74	C-reactive protein	Homo sapiens	224-242
12841342-1	2003	The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later.	cerivastatin	62-74	C-reactive protein	Homo sapiens	244-247
12841342-1	2003	The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later.	cerivastatin	62-74	interleukin 6	Homo sapiens	250-263
12841342-1	2003	The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later.	cerivastatin	62-74	interleukin 6	Homo sapiens	265-269
12841342-1	2003	The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later.	cerivastatin	62-74	C-X-C motif chemokine ligand 8	Homo sapiens	275-288
12841342-1	2003	The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later.	cerivastatin	62-74	C-X-C motif chemokine ligand 8	Homo sapiens	290-294
12841342-6	2003	In patients treated with cerivastatin (group C+, n = 13) we observed decrease in the CRP level (-6.73 +/- 3.93 mg/L); on the other hand, in group C- (n = 17) the CRP level increased (+7.92 +/- 2.77 mg/L, p = 0.004).	cerivastatin	25-37	C-reactive protein	Homo sapiens	85-88
12841342-6	2003	In patients treated with cerivastatin (group C+, n = 13) we observed decrease in the CRP level (-6.73 +/- 3.93 mg/L); on the other hand, in group C- (n = 17) the CRP level increased (+7.92 +/- 2.77 mg/L, p = 0.004).	cerivastatin	25-37	C-reactive protein	Homo sapiens	162-165
12841342-9	2003	Our results suggest that early treatment with cerivastatin can decrease the serum level of CRP and IL-6 in patients with UAP/NQMI; this might positively influence their prognosis.	cerivastatin	46-58	C-reactive protein	Homo sapiens	91-94
12841342-9	2003	Our results suggest that early treatment with cerivastatin can decrease the serum level of CRP and IL-6 in patients with UAP/NQMI; this might positively influence their prognosis.	cerivastatin	46-58	interleukin 6	Homo sapiens	99-103
12615677-7	2003	Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs).	cerivastatin	41-53	tumor necrosis factor	Homo sapiens	81-114
12615677-7	2003	Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs).	cerivastatin	41-53	intercellular adhesion molecule 1	Homo sapiens	137-141
12615677-7	2003	Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs).	cerivastatin	41-53	lymphotoxin beta receptor	Homo sapiens	146-150
12615677-7	2003	Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs).	cerivastatin	41-53	integrin subunit alpha L	Homo sapiens	151-156
12615677-7	2003	Moreover, simvastatin, atorvastatin, and cerivastatin were found to downregulate tumor necrosis factor (TNF)-alpha-induced expression of CD54 and CD18/CD11a in isolated PBMCs obtained from normal donors as well as TNF-alpha-dependent expression of these CAMs in cultured human umbilical vein endothelial cells (HUVECs).	cerivastatin	41-53	tumor necrosis factor	Homo sapiens	214-223
12531431-8	2003	This hypothesis was supported by the fact that a RhoA inhibitor (C3 exoenzyme) or a dominant negative mutant RhoA (N19RhoA) induced similar effects to those of cerivastatin.	cerivastatin	160-172	ras homolog family member A	Homo sapiens	49-53
12531431-8	2003	This hypothesis was supported by the fact that a RhoA inhibitor (C3 exoenzyme) or a dominant negative mutant RhoA (N19RhoA) induced similar effects to those of cerivastatin.	cerivastatin	160-172	ras homolog family member A	Homo sapiens	109-113
12531431-8	2003	This hypothesis was supported by the fact that a RhoA inhibitor (C3 exoenzyme) or a dominant negative mutant RhoA (N19RhoA) induced similar effects to those of cerivastatin.	cerivastatin	160-172	ras homolog family member A	Homo sapiens	109-113
12531431-9	2003	In conclusion, cerivastatin, by preventing RhoA prenylation, inhibits (i) the RhoA/ROCK pathway, leading to defective actin stress fibres formation responsible for the loss of traction forces required for cell motility and (ii) the RhoA/FAK/AKT signalling pathway that could explain the majority of cancer-related gene modifications described above.	cerivastatin	15-27	ras homolog family member A	Homo sapiens	43-47
12531431-9	2003	In conclusion, cerivastatin, by preventing RhoA prenylation, inhibits (i) the RhoA/ROCK pathway, leading to defective actin stress fibres formation responsible for the loss of traction forces required for cell motility and (ii) the RhoA/FAK/AKT signalling pathway that could explain the majority of cancer-related gene modifications described above.	cerivastatin	15-27	ras homolog family member A	Homo sapiens	78-82
12531431-9	2003	In conclusion, cerivastatin, by preventing RhoA prenylation, inhibits (i) the RhoA/ROCK pathway, leading to defective actin stress fibres formation responsible for the loss of traction forces required for cell motility and (ii) the RhoA/FAK/AKT signalling pathway that could explain the majority of cancer-related gene modifications described above.	cerivastatin	15-27	ras homolog family member A	Homo sapiens	78-82
12531431-9	2003	In conclusion, cerivastatin, by preventing RhoA prenylation, inhibits (i) the RhoA/ROCK pathway, leading to defective actin stress fibres formation responsible for the loss of traction forces required for cell motility and (ii) the RhoA/FAK/AKT signalling pathway that could explain the majority of cancer-related gene modifications described above.	cerivastatin	15-27	protein tyrosine kinase 2	Homo sapiens	237-240
12531431-9	2003	In conclusion, cerivastatin, by preventing RhoA prenylation, inhibits (i) the RhoA/ROCK pathway, leading to defective actin stress fibres formation responsible for the loss of traction forces required for cell motility and (ii) the RhoA/FAK/AKT signalling pathway that could explain the majority of cancer-related gene modifications described above.	cerivastatin	15-27	AKT serine/threonine kinase 1	Homo sapiens	241-244
12605021-7	2003	TSP-1 and TSP-2 mRNA expression was inhibited highly significantly at cerivastatin doses >or=0.01 microM with maximums of 72% and 35%, respectively, at high glucose levels.	cerivastatin	70-82	thrombospondin 1	Homo sapiens	0-5
12605021-7	2003	TSP-1 and TSP-2 mRNA expression was inhibited highly significantly at cerivastatin doses >or=0.01 microM with maximums of 72% and 35%, respectively, at high glucose levels.	cerivastatin	70-82	thrombospondin 2	Homo sapiens	10-15
12573493-6	2003	Cerivastatin and fluvastatin increase CYP 2C mRNA and protein in native and cultured endothelial cells, and enhance the bradykinin-induced NO/PGI(2)-independent relaxation of arterial segments as well as the generation of reactive oxygen species.	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	38-44
12573493-6	2003	Cerivastatin and fluvastatin increase CYP 2C mRNA and protein in native and cultured endothelial cells, and enhance the bradykinin-induced NO/PGI(2)-independent relaxation of arterial segments as well as the generation of reactive oxygen species.	cerivastatin	0-12	kininogen 1	Homo sapiens	120-130
12588756-4	2003	The mRNA of GTPCH, as well as of eNOS, was upregulated in HUVECs treated with cerivastatin.	cerivastatin	78-90	GTP cyclohydrolase 1	Homo sapiens	12-17
12588756-9	2003	In the presence of cerivastatin, the TNF-alpha-mediated increase in GTPCH mRNA was enhanced, and the TNF-alpha-mediated decrease in eNOS mRNA was attenuated.	cerivastatin	19-31	tumor necrosis factor	Homo sapiens	37-46
12588756-9	2003	In the presence of cerivastatin, the TNF-alpha-mediated increase in GTPCH mRNA was enhanced, and the TNF-alpha-mediated decrease in eNOS mRNA was attenuated.	cerivastatin	19-31	GTP cyclohydrolase 1	Homo sapiens	68-73
12588756-9	2003	In the presence of cerivastatin, the TNF-alpha-mediated increase in GTPCH mRNA was enhanced, and the TNF-alpha-mediated decrease in eNOS mRNA was attenuated.	cerivastatin	19-31	tumor necrosis factor	Homo sapiens	101-110
12525734-4	2003	Cerivastatin myotoxicity might be related to a depletion of essential metabolites needed to anchor COX subunit I to mitochondrial membrane.	cerivastatin	0-12	cytochrome c oxidase subunit 8A	Homo sapiens	99-102
12605027-7	2003	Cerivastatin increased myocardial eNOS mRNA and NOS activity and by 52% and 58% (P < 0.05), respectively.	cerivastatin	0-12	nitric oxide synthase 3	Rattus norvegicus	34-38
12605027-8	2003	Cardioprotection and upregulation of eNOS activity evoked by cerivastatin were not observed in rats cotreated with l-NAME.	cerivastatin	61-73	nitric oxide synthase 3	Rattus norvegicus	37-41
12535733-2	2003	We investigated the effect of HMG-CoA reductase inhibitor cerivastatin on iNOS expression in cultured rat vascular smooth muscle cells (VSMCs).	cerivastatin	58-70	nitric oxide synthase 2	Rattus norvegicus	74-78
12535733-5	2003	Treatment of VSMCs with cerivastatin (10(-7)-10(-5) mol/l), which inhibits isoprenylation of Rho and other small G proteins, significantly increased nitrite/nitrate (NOx) production and upregulated the expression of iNOS mRNA in IL-1beta-stimulated VSMCs.	cerivastatin	24-36	nitric oxide synthase 2	Rattus norvegicus	216-220
12535733-5	2003	Treatment of VSMCs with cerivastatin (10(-7)-10(-5) mol/l), which inhibits isoprenylation of Rho and other small G proteins, significantly increased nitrite/nitrate (NOx) production and upregulated the expression of iNOS mRNA in IL-1beta-stimulated VSMCs.	cerivastatin	24-36	interleukin 1 beta	Rattus norvegicus	229-237
12535733-9	2003	Our study suggests that cerivastatin stimulates iNOS expression in IL-1beta treated VSMCs by its inhibitory effect on Rho/Rho kinase pathway.	cerivastatin	24-36	nitric oxide synthase 2	Rattus norvegicus	48-52
12535733-9	2003	Our study suggests that cerivastatin stimulates iNOS expression in IL-1beta treated VSMCs by its inhibitory effect on Rho/Rho kinase pathway.	cerivastatin	24-36	interleukin 1 beta	Rattus norvegicus	67-75
12535733-10	2003	In addition, this effect of cerivastatin, by enhancing iNOS expression, may contribute to the prevention of restenosis after percutaneous coronary intervention and protect against atherothrombosis.	cerivastatin	28-40	nitric oxide synthase 2	Rattus norvegicus	55-59
12538631-3	2003	Hydrophobic statins including simvastatin, atorvastatin, and cerivastatin-but not a hydrophilic statin, pravastatin-markedly increased VEGF mRNA abundance in nontransformed osteoblastic cells (MC3T3-E1).	cerivastatin	61-73	vascular endothelial growth factor A	Mus musculus	135-139
12740486-4	2003	Cerivastatin and GGTI-286, but not FTI-277, suppressed the PDGF-BB-induced [3H] thymidine incorporation and activation of ornitine decarboxylase (ODC), both of which were fully recovered by the addition of GGPP, but not FPP.	cerivastatin	0-12	ornithine decarboxylase 1	Rattus norvegicus	122-144
12740486-4	2003	Cerivastatin and GGTI-286, but not FTI-277, suppressed the PDGF-BB-induced [3H] thymidine incorporation and activation of ornitine decarboxylase (ODC), both of which were fully recovered by the addition of GGPP, but not FPP.	cerivastatin	0-12	ornithine decarboxylase 1	Rattus norvegicus	146-149
12525568-0	2003	Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3.	cerivastatin	0-12	interleukin 3	Homo sapiens	38-42
12525568-0	2003	Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3.	cerivastatin	0-12	immunoglobulin heavy constant epsilon	Homo sapiens	73-76
12525568-0	2003	Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3.	cerivastatin	0-12	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	186-192
12525568-0	2003	Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3.	cerivastatin	0-12	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	193-199
12525568-4	2003	Preincubation of blood basophils with cerivastatin or atorvastatin (0.1-100 microM) for 24 h reduced their capacity to release histamine on immunoglobulin E (IgE)-dependent stimulation in a dose-dependent manner.	cerivastatin	38-50	immunoglobulin heavy constant epsilon	Homo sapiens	140-156
12525568-4	2003	Preincubation of blood basophils with cerivastatin or atorvastatin (0.1-100 microM) for 24 h reduced their capacity to release histamine on immunoglobulin E (IgE)-dependent stimulation in a dose-dependent manner.	cerivastatin	38-50	immunoglobulin heavy constant epsilon	Homo sapiens	158-161
12433802-5	2002	The present in vitro findings suggest that inhibition of CYP2C8 activity by gemfibrozil at least partially explains the interaction between gemfibrozil and cerivastatin.	cerivastatin	156-168	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	57-63
12433802-6	2002	The formation of M-23 acid from cerivastatin is mediated mainly by CYP2C8 and thus may be a suitable CYP2C8 probe reaction.	cerivastatin	32-44	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	67-73
12433802-0	2002	Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.	cerivastatin	37-49	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	21-27
12433802-6	2002	The formation of M-23 acid from cerivastatin is mediated mainly by CYP2C8 and thus may be a suitable CYP2C8 probe reaction.	cerivastatin	32-44	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	101-107
12368225-8	2002	Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE-induced increase in NF-kB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular EC.	cerivastatin	0-12	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	173-177
12368225-8	2002	Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE-induced increase in NF-kB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular EC.	cerivastatin	0-12	vascular endothelial growth factor A	Homo sapiens	188-192
12368225-10	2002	By blocking AGE-RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.	cerivastatin	41-53	long intergenic non-protein coding RNA 914	Homo sapiens	16-20
12444208-10	2002	Cerivastatin inhibited ACE activity by 30%.	cerivastatin	0-12	angiotensin I converting enzyme	Homo sapiens	23-26
12444208-13	2002	Cerivastatin inhibited TGF-beta(1) gene upregulation by 25%.	cerivastatin	0-12	transforming growth factor beta 1	Homo sapiens	23-34
12512694-0	2002	Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis.	cerivastatin	0-12	nitric oxide synthase 3	Homo sapiens	50-54
12512694-3	2002	The long-term effect of cerivastatin on NO release from endothelial cells was determined by using highly sensitive electrochemical microsensors and was correlated with endothelial NO synthase (eNOS) levels.	cerivastatin	24-36	nitric oxide synthase 3	Homo sapiens	193-197
12512694-5	2002	Cerivastatin increased spontaneous (by 53% +/- 6) and an eNOS-stimulated NO release (by 41 +/- 6% for calcium ionophore and by 47 +/- 5% acetylcholine) as well as eNOS expression (by 118 +/- 6%) in the same concentration-range.	cerivastatin	0-12	nitric oxide synthase 3	Homo sapiens	57-61
12512694-6	2002	Cerivastatin-dependent increase in both NO release and eNOS expression was revealed after approximately 4 h of exposure reaching the maximum after approximately 10 h. Co-treatment with MVA or GGPP, but not FPP or LDL, reversed the effects of cerivastatin.	cerivastatin	0-12	nitric oxide synthase 3	Homo sapiens	55-59
12512694-6	2002	Cerivastatin-dependent increase in both NO release and eNOS expression was revealed after approximately 4 h of exposure reaching the maximum after approximately 10 h. Co-treatment with MVA or GGPP, but not FPP or LDL, reversed the effects of cerivastatin.	cerivastatin	242-254	nitric oxide synthase 3	Homo sapiens	55-59
12512694-7	2002	These findings indicate that the long-term effect of cerivastatin resulting in enhanced NO bioavailabilty in endothelial cell is, at least in part, due to up-regulation of eNOS by blocking isoprenoids synthesis.	cerivastatin	53-65	nitric oxide synthase 3	Homo sapiens	172-176
12501010-0	2002	Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity.	cerivastatin	0-12	serpin family E member 1	Homo sapiens	53-86
12501010-0	2002	Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity.	cerivastatin	0-12	serpin family E member 1	Homo sapiens	88-93
12501010-0	2002	Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity.	cerivastatin	0-12	serpin family E member 1	Homo sapiens	190-195
12501010-2	2002	In this report, molecular mechanisms of the inhibitory effect on plasminogen activator inhibitor type 1 (PAI-1) expression produced by cerivastatin (CRV), the most active compound in this class, were studied using monocultures of human endothelial cell line (EA.hy 926).	cerivastatin	135-147	serpin family E member 1	Homo sapiens	65-103
12501010-2	2002	In this report, molecular mechanisms of the inhibitory effect on plasminogen activator inhibitor type 1 (PAI-1) expression produced by cerivastatin (CRV), the most active compound in this class, were studied using monocultures of human endothelial cell line (EA.hy 926).	cerivastatin	135-147	serpin family E member 1	Homo sapiens	105-110
12169389-0	2002	Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK).	cerivastatin	55-67	protein tyrosine kinase 2	Homo sapiens	111-114
12398901-3	2002	Cerivastatin significantly reduced the increase in [14C]phenylalanine incorporation, ANP peptide release, ANP mRNA expression and cell size induced by endothelin, but pravastatin did not.	cerivastatin	0-12	natriuretic peptide A	Rattus norvegicus	85-88
12398901-3	2002	Cerivastatin significantly reduced the increase in [14C]phenylalanine incorporation, ANP peptide release, ANP mRNA expression and cell size induced by endothelin, but pravastatin did not.	cerivastatin	0-12	natriuretic peptide A	Rattus norvegicus	106-109
12398901-4	2002	Exogenous mevalonate completely prevented the inhibitory effect of cerivastatin on [14C]phenylalanine incorporation, ANP release and cell size.	cerivastatin	67-79	natriuretic peptide A	Rattus norvegicus	117-120
12237173-10	2002	Pretreating the cells with the 3-hydroxy-3-methylglutaryl CoA (HMG CoA) reductase inhibitor Cerivastatin reduced IL-6 release.	cerivastatin	92-104	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	31-81
12237173-10	2002	Pretreating the cells with the 3-hydroxy-3-methylglutaryl CoA (HMG CoA) reductase inhibitor Cerivastatin reduced IL-6 release.	cerivastatin	92-104	interleukin 6	Homo sapiens	113-117
12510809-4	2003	In vitro, cerivastatin inhibited the parathyroid hormone (PTH)-stimulated bone resorption.	cerivastatin	10-22	parathyroid hormone	Rattus norvegicus	37-56
12208470-8	2002	Lipophilic cerivastatin also significantly decreased IL-8 production, while hydrophilic pravastatin showed no effect on IL-8 levels.	cerivastatin	11-23	C-X-C motif chemokine ligand 8	Homo sapiens	53-57
12241641-7	2002	Furthermore, 1 mg/kg of cerivastatin significantly inhibited the expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) without lowering serum cholesterol.	cerivastatin	24-36	tumor necrosis factor	Mus musculus	79-106
12241641-7	2002	Furthermore, 1 mg/kg of cerivastatin significantly inhibited the expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) without lowering serum cholesterol.	cerivastatin	24-36	tumor necrosis factor	Mus musculus	108-117
12241641-7	2002	Furthermore, 1 mg/kg of cerivastatin significantly inhibited the expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) without lowering serum cholesterol.	cerivastatin	24-36	interleukin 1 beta	Mus musculus	123-140
12241641-7	2002	Furthermore, 1 mg/kg of cerivastatin significantly inhibited the expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) without lowering serum cholesterol.	cerivastatin	24-36	interleukin 1 beta	Mus musculus	142-150
12145176-0	2002	Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes.	cerivastatin	0-12	insulin	Homo sapiens	22-29
12145176-2	2002	The insulin sensitivity index during the euglycemic-hyperinsulinemic clamp (EHC; 5.4 mmol/l; 80 mU x m(-2) x min(-1)) was increased by cerivastatin treatment (66.39 +/- 3.9 nmol x lean body mass [LBM](-1) x min(-1) x pmol(-1) x l(-1)) as compared with placebo (58.37 +/- 3.69 nmol x LBM(-1) x min(-1) x pmol(-1) x l(- 1); P < 0.01) by 13.7%.	cerivastatin	135-147	insulin	Homo sapiens	4-11
12142351-12	2002	Rac-1 inactivation by Clostridium difficile toxin B inhibited the cerivastatin-induced oxygen radical production in human umbilical vein endothelial cells.	cerivastatin	66-78	Rac family small GTPase 1	Mus musculus	0-5
12131557-6	2002	Similarly, the level of phosphorylated p38 was also decreased by cerivastatin.	cerivastatin	65-77	mitogen activated protein kinase 14	Rattus norvegicus	39-42
12131557-7	2002	In contrast, cerivastatin dose-dependently activated the phosphorylation of both c-jun NH2-terminal protein kinase and activating transcription factor-2, and these activations were abolished by the addition of mevalonate.	cerivastatin	13-25	activating transcription factor 2	Rattus norvegicus	119-152
12131557-8	2002	The levels of phosphorylated Akt and p70 S6 kinase as well as those of Bcl-2 were dose-dependently reduced by cerivastatin, and these reductions were abolished by the addition of mevalonate.	cerivastatin	110-122	AKT serine/threonine kinase 1	Rattus norvegicus	29-32
12131557-8	2002	The levels of phosphorylated Akt and p70 S6 kinase as well as those of Bcl-2 were dose-dependently reduced by cerivastatin, and these reductions were abolished by the addition of mevalonate.	cerivastatin	110-122	BCL2, apoptosis regulator	Rattus norvegicus	71-76
12131557-9	2002	Cerivastatin could dose-dependently elevate the levels of CPP32/caspase-3 activity and cytoplasmic histone-associated DNA fragments in VSMCs without causing cytotoxicity.	cerivastatin	0-12	caspase 3	Rattus norvegicus	58-63
12131557-9	2002	Cerivastatin could dose-dependently elevate the levels of CPP32/caspase-3 activity and cytoplasmic histone-associated DNA fragments in VSMCs without causing cytotoxicity.	cerivastatin	0-12	caspase 3	Rattus norvegicus	64-73
12031711-1	2002	OBJECTIVE: We investigated the effects of the statins, cerivastatin and fluvastatin, on the induction of nitric oxide (NO) production in vascular smooth muscle cells (VSMC) stimulated by interleukin-1beta (IL-1) or in combination with interferon-gamma (IFN).	cerivastatin	55-67	interleukin 1 beta	Homo sapiens	187-204
12048120-5	2002	Cerivastatin and pravastatin reduced the levels of TF antigen and mRNA.	cerivastatin	0-12	coagulation factor III, tissue factor	Homo sapiens	51-53
12067916-7	2002	Thrombin-activated platelets primed neutrophils for enhanced oxygen-free radical release on triggering with formyl-Met-Leu-Phe, reduced by cerivastatin and simvastatin treatment of platelets.	cerivastatin	139-151	coagulation factor II, thrombin	Homo sapiens	0-8
12096274-0	2002	A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.	cerivastatin	61-73	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	2-49
12096274-0	2002	A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.	cerivastatin	61-73	matrix metallopeptidase 9	Homo sapiens	100-126
12096274-8	2002	Cerivastatin (0.001 to 0.1 micromol/L) significantly reduced the tissue levels of both total and active MMP-9 in a concentration-dependent manner (P <.001), and the production of tissue inhibitor of MMP-1 was unaffected.	cerivastatin	0-12	matrix metallopeptidase 9	Homo sapiens	104-109
12096274-8	2002	Cerivastatin (0.001 to 0.1 micromol/L) significantly reduced the tissue levels of both total and active MMP-9 in a concentration-dependent manner (P <.001), and the production of tissue inhibitor of MMP-1 was unaffected.	cerivastatin	0-12	matrix metallopeptidase 1	Homo sapiens	202-207
12096274-10	2002	CONCLUSION: These results suggest that cerivastatin can directly modulate the biology of the AAA wall and suppress MMP-9 production in the AAA wall by inhibiting the activation of neutrophils and macrophages, indicating that statin therapy could be useful for the prevention or treatment of AAA.	cerivastatin	39-51	matrix metallopeptidase 9	Homo sapiens	115-120
11779144-4	2002	Although the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors cerivastatin, fluvastatin, and pitavastatin were not ligands for these three nuclear receptors in the CARLA, they induced transcriptional activation of PPARalpha/RXRalpha, PPARdelta/RXRalpha, and PPARgamma2/RXRalpha.	cerivastatin	82-94	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	13-70
11864921-2	2002	Therefore, measurements of biologically active NO and O2- in endothelium after exposure to the HMG-CoA reductase inhibitor cerivastatin were undertaken to evaluate its potential effect on NO biological activity.	cerivastatin	123-135	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	95-112
11864921-8	2002	In contrast to the initial effect, the sustained effect of cerivastatin was shown at concentrations approximately 100-fold lower and was dependent on inhibition of endothelial HMG-CoA reductase.	cerivastatin	59-71	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	176-193
11976279-4	2002	Pre-treatment with 1 - 10 microM atorvastatin, cerivastatin or pravastatin decreased TNFalpha plus IFNgamma stimulated iNOS expression in the endothelium irrespective of the presence of the HMG-CoA reductase product mevalonate (400 microM).	cerivastatin	47-59	tumor necrosis factor	Homo sapiens	85-93
11976279-4	2002	Pre-treatment with 1 - 10 microM atorvastatin, cerivastatin or pravastatin decreased TNFalpha plus IFNgamma stimulated iNOS expression in the endothelium irrespective of the presence of the HMG-CoA reductase product mevalonate (400 microM).	cerivastatin	47-59	interferon gamma	Homo sapiens	99-107
11976279-4	2002	Pre-treatment with 1 - 10 microM atorvastatin, cerivastatin or pravastatin decreased TNFalpha plus IFNgamma stimulated iNOS expression in the endothelium irrespective of the presence of the HMG-CoA reductase product mevalonate (400 microM).	cerivastatin	47-59	nitric oxide synthase 2	Homo sapiens	119-123
11950701-8	2002	These effects are reversed by GGPP, suggesting that the inhibitory effect of cerivastatin is related to RhoA inactivation.	cerivastatin	77-89	ras homolog family member A	Gallus gallus	104-108
11927220-0	2002	HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals.	cerivastatin	28-40	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	0-17
11927220-3	2002	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor cerivastatin has been shown to suppress ICAM-1 expression in acute inflammatory responses.	cerivastatin	68-80	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	0-57
11927220-3	2002	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor cerivastatin has been shown to suppress ICAM-1 expression in acute inflammatory responses.	cerivastatin	68-80	intercellular adhesion molecule 1	Rattus norvegicus	108-114
11927220-9	2002	The Interleukin-2 concentration of supernatant in MLR cultures in the cerivastatin-treated group was lower than in the control group.	cerivastatin	70-82	interleukin 2	Rattus norvegicus	4-17
11927220-11	2002	CONCLUSIONS: The HMG-CoA reductase inhibitor cerivastatin effectively suppressed acute graft rejection, possibly by blocking intercellular signals via ICAM/LFA-1, and cerivastatin may be a candidate for treating patients with hyperlipidemia who undergo organ transplantation.	cerivastatin	45-57	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	17-34
11927220-11	2002	CONCLUSIONS: The HMG-CoA reductase inhibitor cerivastatin effectively suppressed acute graft rejection, possibly by blocking intercellular signals via ICAM/LFA-1, and cerivastatin may be a candidate for treating patients with hyperlipidemia who undergo organ transplantation.	cerivastatin	45-57	integrin subunit alpha L	Homo sapiens	156-161
11779144-5	2002	Moreover, cerivastatin, fluvastatin, and pitavastatin synergistically and dose-dependently increased the transcriptional activation of PPARalpha/RXRalpha induced by bezafibrate.	cerivastatin	10-22	peroxisome proliferator activated receptor alpha	Homo sapiens	135-144
11779144-5	2002	Moreover, cerivastatin, fluvastatin, and pitavastatin synergistically and dose-dependently increased the transcriptional activation of PPARalpha/RXRalpha induced by bezafibrate.	cerivastatin	10-22	retinoid X receptor alpha	Homo sapiens	145-153
11779144-6	2002	In addition, the cerivastatin-induced transcriptional activation of PPARalpha/RXRalpha was decreased by addition of mevalonate, farnesol, geranylgeraniol, or cholesterol and by co-transfection with sterol regulatory element-binding protein-1 (SREBP-1).	cerivastatin	17-29	peroxisome proliferator activated receptor alpha	Homo sapiens	68-77
11779144-6	2002	In addition, the cerivastatin-induced transcriptional activation of PPARalpha/RXRalpha was decreased by addition of mevalonate, farnesol, geranylgeraniol, or cholesterol and by co-transfection with sterol regulatory element-binding protein-1 (SREBP-1).	cerivastatin	17-29	retinoid X receptor alpha	Homo sapiens	78-86
11779144-6	2002	In addition, the cerivastatin-induced transcriptional activation of PPARalpha/RXRalpha was decreased by addition of mevalonate, farnesol, geranylgeraniol, or cholesterol and by co-transfection with sterol regulatory element-binding protein-1 (SREBP-1).	cerivastatin	17-29	sterol regulatory element binding transcription factor 1	Homo sapiens	198-241
11779144-6	2002	In addition, the cerivastatin-induced transcriptional activation of PPARalpha/RXRalpha was decreased by addition of mevalonate, farnesol, geranylgeraniol, or cholesterol and by co-transfection with sterol regulatory element-binding protein-1 (SREBP-1).	cerivastatin	17-29	sterol regulatory element binding transcription factor 1	Homo sapiens	243-250
12036392-10	2002	Cerivastatin is also metabolised by CYP2C8.	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	36-42
11742861-4	2001	Cerivastatin and fluvastatin reduced the AT(1)-R mRNA and the AT(1)-R protein levels; however, pravastatin lacked this effect.	cerivastatin	0-12	angiotensin II receptor type 1	Homo sapiens	41-48
11735122-3	2001	Pretreatment of monocytic cells (U937, THP-1, human CD14(+) monocytes) with 0.01-10 microM concentrations of atorvastatin, cerivastatin, or simvastatin significantly reduced cell adhesion to endothelium.	cerivastatin	123-135	GLI family zinc finger 2	Homo sapiens	39-44
11735122-6	2001	Cerivastatin also reduced PMA induction of NF-kappaB.	cerivastatin	0-12	nuclear factor kappa B subunit 1	Homo sapiens	43-52
11742861-4	2001	Cerivastatin and fluvastatin reduced the AT(1)-R mRNA and the AT(1)-R protein levels; however, pravastatin lacked this effect.	cerivastatin	0-12	angiotensin II receptor type 1	Homo sapiens	62-69
11742861-6	2001	Coincubation of VSMCs with mevalonate or geranylgeranyl pyrophosphate but not with farnesyl pyrophosphate reversed the cerivastatin-induced AT(1)-R downregulation.	cerivastatin	119-131	angiotensin II receptor type 1	Homo sapiens	140-147
11742861-5	2001	Cerivastatin and fluvastatin suppressed the AT(1)-R promoter activity measured by luciferase assay but did not affect AT(1)-R mRNA stability, suggesting that the suppression occurs at the transcriptional level.	cerivastatin	0-12	angiotensin II receptor type 1	Homo sapiens	44-51
11742861-8	2001	Treatment with cerivastatin for 24 hours reduced the calcium response of VSMCs to Ang II.	cerivastatin	15-27	angiotensinogen	Homo sapiens	82-88
11500171-6	2001	Cerivastatin [10 pM to 100 microM] decreased leukocyte chemotaxis towards interleukin-8 or RANTES.	cerivastatin	0-12	C-X-C motif chemokine ligand 8	Homo sapiens	74-87
11799261-7	2001	CONCLUSION: The use of cerivastatin is associated with decreased microalbuminuria and plasma and urinary ET-1 levels in microalbuminuric patients with type 2 diabetic mellitus and speculate that this may represent an amelioration of renal injury.	cerivastatin	23-35	endothelin 1	Homo sapiens	105-109
11591621-7	2001	Cerivastatin treatment upregulated eNOS expression and reduced the interaction of the cytosolic protein with the 3"-untranslated region of eNOS mRNA.	cerivastatin	0-12	nitric oxide synthase, endothelial	Oryctolagus cuniculus	35-39
11591621-7	2001	Cerivastatin treatment upregulated eNOS expression and reduced the interaction of the cytosolic protein with the 3"-untranslated region of eNOS mRNA.	cerivastatin	0-12	nitric oxide synthase, endothelial	Oryctolagus cuniculus	139-143
11591621-8	2001	Mononuclear cells from hypercholesterolemic rabbits also showed a marked reduction of eNOS expression and eNOS mRNA stability and an increase in binding activity of the cytosolic protein, which were also prevented by cerivastatin treatment.	cerivastatin	217-229	nitric oxide synthase, endothelial	Oryctolagus cuniculus	86-90
11591621-8	2001	Mononuclear cells from hypercholesterolemic rabbits also showed a marked reduction of eNOS expression and eNOS mRNA stability and an increase in binding activity of the cytosolic protein, which were also prevented by cerivastatin treatment.	cerivastatin	217-229	nitric oxide synthase, endothelial	Oryctolagus cuniculus	106-110
11591621-9	2001	CONCLUSIONS: These results demonstrate the presence of a 60-kDa protein that binds to eNOS mRNA and reductions in eNOS expression in both vascular wall and mononuclear cells that are prevented by cerivastatin.	cerivastatin	196-208	nitric oxide synthase, endothelial	Oryctolagus cuniculus	86-90
11591621-9	2001	CONCLUSIONS: These results demonstrate the presence of a 60-kDa protein that binds to eNOS mRNA and reductions in eNOS expression in both vascular wall and mononuclear cells that are prevented by cerivastatin.	cerivastatin	196-208	nitric oxide synthase, endothelial	Oryctolagus cuniculus	114-118
11641268-0	2001	Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia.	cerivastatin	83-95	nitric oxide synthase 3, endothelial cell	Mus musculus	0-33
11641268-0	2001	Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia.	cerivastatin	83-95	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	55-72
11641268-7	2001	Anti-CD31 immunostaining revealed that cerivastatin significantly increased the capillary density.	cerivastatin	39-51	platelet/endothelial cell adhesion molecule 1	Mus musculus	5-9
11641268-8	2001	Endothelial nitric oxide synthase (eNOS) activity was enhanced markedly in the mice treated with cerivastatin.	cerivastatin	97-109	nitric oxide synthase 3, endothelial cell	Mus musculus	0-33
11641268-8	2001	Endothelial nitric oxide synthase (eNOS) activity was enhanced markedly in the mice treated with cerivastatin.	cerivastatin	97-109	nitric oxide synthase 3, endothelial cell	Mus musculus	35-39
11641268-9	2001	The angiogenic effect of cerivastatin was abrogated in eNOS deficient (eNOS-/-) mice.	cerivastatin	25-37	nitric oxide synthase 3, endothelial cell	Mus musculus	55-59
11641268-9	2001	The angiogenic effect of cerivastatin was abrogated in eNOS deficient (eNOS-/-) mice.	cerivastatin	25-37	nitric oxide synthase 3, endothelial cell	Mus musculus	71-79
11641268-10	2001	These results indicate that eNOS is essential for cerivastatin to promote collateral growth in response to ischemia.	cerivastatin	50-62	nitric oxide synthase 3, endothelial cell	Mus musculus	28-32
11500171-6	2001	Cerivastatin [10 pM to 100 microM] decreased leukocyte chemotaxis towards interleukin-8 or RANTES.	cerivastatin	0-12	C-C motif chemokine ligand 5	Homo sapiens	91-97
11526915-0	2001	In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor.	cerivastatin	31-43	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	64-81
11470741-8	2001	Moreover, cerivastatin was also shown to induce inactivation of NFkappaB, in a RhoA inhibition-dependent manner, resulting in a decrease in urokinase and metalloproteinase-9 expression, two proteases involved in cell migration.	cerivastatin	10-22	nuclear factor kappa B subunit 1	Homo sapiens	64-72
11470741-8	2001	Moreover, cerivastatin was also shown to induce inactivation of NFkappaB, in a RhoA inhibition-dependent manner, resulting in a decrease in urokinase and metalloproteinase-9 expression, two proteases involved in cell migration.	cerivastatin	10-22	ras homolog family member A	Homo sapiens	79-83
11470741-4	2001	In MDA-MB-231 cells, an aggressive breast cancer cell line with spontaneous activation of Ras and NFkappaB and overexpression of RhoA, cerivastatin induced inhibition of both cell proliferation and invasion through Matrigel.	cerivastatin	135-147	ras homolog family member A	Homo sapiens	129-133
11479256-5	2001	Compared with control dTGR, dTGR treated with cerivastatin had reduced mortality, blood pressure, cardiac hypertrophy, macrophage infiltration, and collagen I, laminin, and fibronectin deposition.	cerivastatin	46-58	fibronectin 1	Homo sapiens	173-184
11584328-7	2001	Several drugs have been shown to significantly inhibit the CYP3A4 pathway; in combination with statins such as lovastatin, simvastatin, atorvastatin, and cerivastatin, they have been shown to elevate serum concentrations of these statins, or may increase the risk of myopathy.	cerivastatin	154-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
11451746-8	2001	Cerivastatin significantly reduced F-actin content in U937 cells and inhibited RhoA translocation, whereas preincubation with C3 exoenzyme reduced U937 adhesion under flow.	cerivastatin	0-12	ras homolog family member A	Homo sapiens	79-83
11451746-9	2001	Cerivastatin reduces monocyte adhesion to vascular endothelium under physiological flow conditions via downregulation of integrin adhesion molecules and inhibition of actin polymerization via RhoA inactivation.	cerivastatin	0-12	ras homolog family member A	Homo sapiens	192-196
11411766-8	2001	We also observed that cerivastatin blocked ERK1/2 phosphorylation in vivo and in vitro.	cerivastatin	22-34	mitogen-activated protein kinase 3	Homo sapiens	43-49
11309234-0	2001	The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor.	cerivastatin	42-54	prostaglandin I2 receptor	Homo sapiens	76-98
11406909-7	2001	Incremental cost-effectiveness ratios in comparison with the lowest cost treatment (cerivastatin) were 141 Pounds per additional patient achieving target LDL-C with atorvastatin, and 275 Pounds with simvastatin.	cerivastatin	84-96	component of oligomeric golgi complex 2	Homo sapiens	154-159
11208689-0	2001	An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.	cerivastatin	32-44	tissue factor	Oryctolagus cuniculus	120-133
11250431-0	2001	HMG-COA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals.	cerivastatin	28-40	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	0-17
11238259-0	2001	Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.	cerivastatin	43-55	C-reactive protein	Homo sapiens	19-37
11238259-4	2001	Overall, cerivastatin resulted in a 13.3% reduction in median CRP levels (P:<0.001) and a 24.5% reduction in mean CRP levels (P:<0.001).	cerivastatin	9-21	C-reactive protein	Homo sapiens	62-65
11238259-4	2001	Overall, cerivastatin resulted in a 13.3% reduction in median CRP levels (P:<0.001) and a 24.5% reduction in mean CRP levels (P:<0.001).	cerivastatin	9-21	C-reactive protein	Homo sapiens	117-120
11238259-8	2001	CONCLUSIONS: Among 785 patients with primary hypercholesterolemia, CRP levels were significantly reduced within 8 weeks of initiating cerivastatin therapy in a lipid-independent manner.	cerivastatin	134-146	C-reactive protein	Homo sapiens	67-70
11223427-0	2001	Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins.	cerivastatin	0-12	tumor necrosis factor	Bos taurus	22-49
11223427-0	2001	Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins.	cerivastatin	0-12	nitric oxide synthase 3	Bos taurus	76-109
11223427-3	2001	The aim of the present study was to analyze the effect of cerivastatin, a novel HMG CoA reductase inhibitor, on tumor necrosis factor-alpha (TNF-alpha)-induced downregulation of eNOS protein expression in bovine aortic endothelial cells (BAEC).	cerivastatin	58-70	tumor necrosis factor	Bos taurus	112-139
11223427-3	2001	The aim of the present study was to analyze the effect of cerivastatin, a novel HMG CoA reductase inhibitor, on tumor necrosis factor-alpha (TNF-alpha)-induced downregulation of eNOS protein expression in bovine aortic endothelial cells (BAEC).	cerivastatin	58-70	tumor necrosis factor	Bos taurus	141-150
11223427-3	2001	The aim of the present study was to analyze the effect of cerivastatin, a novel HMG CoA reductase inhibitor, on tumor necrosis factor-alpha (TNF-alpha)-induced downregulation of eNOS protein expression in bovine aortic endothelial cells (BAEC).	cerivastatin	58-70	nitric oxide synthase 3	Bos taurus	178-182
11223427-6	2001	Cerivastatin prevented TNF-alpha-induced downregulation of eNOS protein expression in a concentration-dependent manner (10(-8) to 10(-5) M).	cerivastatin	0-12	tumor necrosis factor	Bos taurus	23-32
11223427-6	2001	Cerivastatin prevented TNF-alpha-induced downregulation of eNOS protein expression in a concentration-dependent manner (10(-8) to 10(-5) M).	cerivastatin	0-12	nitric oxide synthase 3	Bos taurus	59-63
11223427-7	2001	Cerivastatin also prevented the binding of the cytosolic proteins to 3"-UTR of eNOS mRNA and was associated with eNOS mRNA stabilization.	cerivastatin	0-12	nitric oxide synthase 3	Bos taurus	79-83
11223427-7	2001	Cerivastatin also prevented the binding of the cytosolic proteins to 3"-UTR of eNOS mRNA and was associated with eNOS mRNA stabilization.	cerivastatin	0-12	nitric oxide synthase 3	Bos taurus	113-117
11223427-12	2001	The effect of cerivastatin on eNOS expression and the binding activity of the cytosolic proteins were reversed by coincubation with L-mevalonate.	cerivastatin	14-26	nitric oxide synthase 3	Bos taurus	30-34
11223427-14	2001	The effect of cerivastatin on the regulation of eNOS expression was independent of NF-kappaB mobilization by TNF-alpha.	cerivastatin	14-26	nitric oxide synthase 3	Bos taurus	48-52
11307781-6	2001	Cerivastatin has a dual hepatic metabolism pathway, via the CYP3A4 and CYP2C8 isoenzymes of cytochrome P450; therefore no potentially significant drug interactions with other CYP3A4 inhibitors, for instance erythromycin and itraconazole, have been reported.	cerivastatin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
11307781-6	2001	Cerivastatin has a dual hepatic metabolism pathway, via the CYP3A4 and CYP2C8 isoenzymes of cytochrome P450; therefore no potentially significant drug interactions with other CYP3A4 inhibitors, for instance erythromycin and itraconazole, have been reported.	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	71-77
11307781-6	2001	Cerivastatin has a dual hepatic metabolism pathway, via the CYP3A4 and CYP2C8 isoenzymes of cytochrome P450; therefore no potentially significant drug interactions with other CYP3A4 inhibitors, for instance erythromycin and itraconazole, have been reported.	cerivastatin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-181
11208689-6	2001	Macrophage expression of MMP-1, MMP-3, MMP-9, and TF also decreased with cerivastatin treatment.	cerivastatin	73-85	interstitial collagenase	Oryctolagus cuniculus	25-30
11208689-6	2001	Macrophage expression of MMP-1, MMP-3, MMP-9, and TF also decreased with cerivastatin treatment.	cerivastatin	73-85	stromelysin-1	Oryctolagus cuniculus	32-37
11208689-6	2001	Macrophage expression of MMP-1, MMP-3, MMP-9, and TF also decreased with cerivastatin treatment.	cerivastatin	73-85	matrix metalloproteinase-9	Oryctolagus cuniculus	39-44
11208689-6	2001	Macrophage expression of MMP-1, MMP-3, MMP-9, and TF also decreased with cerivastatin treatment.	cerivastatin	73-85	tissue factor	Oryctolagus cuniculus	50-52
11208689-8	2001	Cerivastatin treatment (>or=0.01 micromol/L) also reduced growth, proteolytic activity due to MMP-9, and TF expression in cultured human monocyte/macrophages.	cerivastatin	0-12	matrix metallopeptidase 9	Homo sapiens	97-102
11079678-1	2000	OBJECTIVES: This study examined effects of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor cerivastatin on human saphenous vein (SV), endothelial cells (EC) and smooth muscle cells (SMC).	cerivastatin	104-116	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	43-93
11197581-12	2001	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).	cerivastatin	142-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-120
11079678-8	2000	RESULTS: Cerivastatin (10(-9) to 10(-6) mol/liter) enhanced eNOS protein expression and NO release (about two-fold) in EC in response to Ca2+ ionophore (10(-6) mol/liter).	cerivastatin	9-21	nitric oxide synthase 3	Homo sapiens	60-64
11079678-11	2000	Cerivastatin reduced the 3H-thymidine incorporation (164 +/- 11%, p < 0.01), inhibited Cdk2 activation and Rb phosphorylation, but did not prevent p27Kip1 down-regulation, nor p42mapk and p70S6K activation.	cerivastatin	0-12	cyclin dependent kinase 2	Homo sapiens	90-94
11079678-11	2000	Cerivastatin reduced the 3H-thymidine incorporation (164 +/- 11%, p < 0.01), inhibited Cdk2 activation and Rb phosphorylation, but did not prevent p27Kip1 down-regulation, nor p42mapk and p70S6K activation.	cerivastatin	0-12	mitogen-activated protein kinase 1	Homo sapiens	179-186
11079678-11	2000	Cerivastatin reduced the 3H-thymidine incorporation (164 +/- 11%, p < 0.01), inhibited Cdk2 activation and Rb phosphorylation, but did not prevent p27Kip1 down-regulation, nor p42mapk and p70S6K activation.	cerivastatin	0-12	ribosomal protein S6 kinase B1	Homo sapiens	191-197
11079678-12	2000	Mevalonate abrogated the effects of cerivastatin on Cdk2 and Rb but only partially rescued the 3H-thymidine incorporation (from 164 +/- 11% to 211 +/- 13%, n = 4, p < 0.01).	cerivastatin	36-48	cyclin dependent kinase 2	Homo sapiens	52-56
11057870-0	2000	Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis.	cerivastatin	0-12	matrix metallopeptidase 9	Homo sapiens	102-107
11061579-2	2000	Cerivastatin is metabolized by cytochrome P450 (CYP)3A4 and CYP2C8.	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	60-66
11057870-4	2000	The present study shows that the expression of u-PA and u-PAR induced by ox-LDL on monocyte surface is suppressed by cerivastatin (a synthetic inhibitor of HMG-CoA reductase, Bayer) from 2 nM.	cerivastatin	117-129	plasminogen activator, urokinase	Homo sapiens	47-51
11057870-4	2000	The present study shows that the expression of u-PA and u-PAR induced by ox-LDL on monocyte surface is suppressed by cerivastatin (a synthetic inhibitor of HMG-CoA reductase, Bayer) from 2 nM.	cerivastatin	117-129	plasminogen activator, urokinase receptor	Homo sapiens	56-61
11057870-6	2000	Furthermore, higher concentrations of cerivastatin (50-100 nM) reduce the expression of u-PA and u-PAR on unstimulated monocytes.	cerivastatin	38-50	plasminogen activator, urokinase	Homo sapiens	88-92
11057870-6	2000	Furthermore, higher concentrations of cerivastatin (50-100 nM) reduce the expression of u-PA and u-PAR on unstimulated monocytes.	cerivastatin	38-50	plasminogen activator, urokinase receptor	Homo sapiens	97-102
11057870-8	2000	The inhibitory effect of cerivastatin on u-PA expression and MMP-9 secretion can be explained by the inhibition of NF-kappa B translocation into the nucleus, as shown by immunofluorescence.	cerivastatin	25-37	plasminogen activator, urokinase	Homo sapiens	41-45
11057870-8	2000	The inhibitory effect of cerivastatin on u-PA expression and MMP-9 secretion can be explained by the inhibition of NF-kappa B translocation into the nucleus, as shown by immunofluorescence.	cerivastatin	25-37	nuclear factor kappa B subunit 1	Homo sapiens	115-125
11005703-12	2000	Atorvastatin, cerivastatin, lovastatin and simvastatin are predominantly metabolised by the CYP3A4 isozyme.	cerivastatin	14-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
11012877-0	2000	Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.	cerivastatin	0-12	angiotensinogen	Homo sapiens	22-36
11012877-2	2000	We used an angiotensin II (Ang II)-dependent model to test the hypothesis that cerivastatin prevents leukocyte adhesion and infiltration, induction of inducible nitric oxide synthase (iNOS), and ameliorates end-organ damage.	cerivastatin	79-91	angiotensinogen	Homo sapiens	11-25
11012877-2	2000	We used an angiotensin II (Ang II)-dependent model to test the hypothesis that cerivastatin prevents leukocyte adhesion and infiltration, induction of inducible nitric oxide synthase (iNOS), and ameliorates end-organ damage.	cerivastatin	79-91	angiotensinogen	Homo sapiens	27-33
11012877-2	2000	We used an angiotensin II (Ang II)-dependent model to test the hypothesis that cerivastatin prevents leukocyte adhesion and infiltration, induction of inducible nitric oxide synthase (iNOS), and ameliorates end-organ damage.	cerivastatin	79-91	nitric oxide synthase 2	Homo sapiens	151-182
11012877-2	2000	We used an angiotensin II (Ang II)-dependent model to test the hypothesis that cerivastatin prevents leukocyte adhesion and infiltration, induction of inducible nitric oxide synthase (iNOS), and ameliorates end-organ damage.	cerivastatin	79-91	nitric oxide synthase 2	Homo sapiens	184-188
11012877-15	2000	In addition, in vitro incubation of vascular smooth muscle cells with cerivastatin (0.5 micromol/L) almost completely prevented the Ang II-induced ERK phosphorylation.	cerivastatin	70-82	angiotensinogen	Homo sapiens	132-138
11012877-16	2000	CONCLUSION: Cerivastatin reduced inflammation, cell proliferation, and iNOS induction, which led to a reduction in cellular damage.	cerivastatin	12-24	nitric oxide synthase 2	Homo sapiens	71-75
11126989-3	2000	Most statins are metabolised by the CYP3A4 izoenzyme (lovastatin, simvastatin, atorvastatin, cerivastatin).	cerivastatin	93-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
10945857-5	2000	to CD-1 mice, serum levels of both TNF-alpha and IL-1beta transiently increased, and peaked at 2 h. After the peak responses of TNF-alpha and IL-1beta, serum levels of nitrite and nitrate increased until at least 8 h. Pretreatment of the mice with cerivastatin (20 mg/kg i.p.	cerivastatin	248-260	tumor necrosis factor	Mus musculus	35-44
10945857-5	2000	to CD-1 mice, serum levels of both TNF-alpha and IL-1beta transiently increased, and peaked at 2 h. After the peak responses of TNF-alpha and IL-1beta, serum levels of nitrite and nitrate increased until at least 8 h. Pretreatment of the mice with cerivastatin (20 mg/kg i.p.	cerivastatin	248-260	interleukin 1 beta	Mus musculus	49-57
10859477-1	2000	The aim of this study was to investigate whether cerivastatin (BAYw6228), a new potent 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, was able to prevent atherogenesis in heterozygous Watanabe heritable-hyperlipidemic (WHHL) rabbits, a model never tested before using this HMG-CoA reductase inhibitor.	cerivastatin	49-61	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	87-137
10976657-12	2000	Cerivastatin is subject to 2 main oxidative biotransformation reactions: demethylation of the benzylic methyl ether moiety leading to the metabolite M-1 [catalysed by cytochrome P450 (CYP) 2C8 and CYP3A4] and stereoselective hydroxylation of one methyl group of the 6-isopropyl substituent leading to the metabolite M-23 (catalysed by CYP2C8).	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	167-192
10976657-12	2000	Cerivastatin is subject to 2 main oxidative biotransformation reactions: demethylation of the benzylic methyl ether moiety leading to the metabolite M-1 [catalysed by cytochrome P450 (CYP) 2C8 and CYP3A4] and stereoselective hydroxylation of one methyl group of the 6-isopropyl substituent leading to the metabolite M-23 (catalysed by CYP2C8).	cerivastatin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	197-203
10976657-12	2000	Cerivastatin is subject to 2 main oxidative biotransformation reactions: demethylation of the benzylic methyl ether moiety leading to the metabolite M-1 [catalysed by cytochrome P450 (CYP) 2C8 and CYP3A4] and stereoselective hydroxylation of one methyl group of the 6-isopropyl substituent leading to the metabolite M-23 (catalysed by CYP2C8).	cerivastatin	0-12	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	335-341
10954025-3	2000	Eight type 2 diabetic patients were examined before treatment with the 3-hydroxy-3-methyl glutaryl coenzyme A (HMGCoA) reductase inhibitor cerivastatin, after 4 weeks on active treatment, and 4 weeks after stopping treatment.	cerivastatin	139-151	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	71-128
10859477-1	2000	The aim of this study was to investigate whether cerivastatin (BAYw6228), a new potent 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, was able to prevent atherogenesis in heterozygous Watanabe heritable-hyperlipidemic (WHHL) rabbits, a model never tested before using this HMG-CoA reductase inhibitor.	cerivastatin	63-71	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	87-137
10694484-0	2000	Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC.	cerivastatin	0-12	intercellular adhesion molecule 1	Bos taurus	51-57
10769273-12	2000	Coincubation with cerivastatin resulted in significantly lower MCP-1 and IL-8 production, whereas the release of TNF-alpha remained unaffected.	cerivastatin	18-30	C-C motif chemokine ligand 2	Homo sapiens	63-68
10769273-12	2000	Coincubation with cerivastatin resulted in significantly lower MCP-1 and IL-8 production, whereas the release of TNF-alpha remained unaffected.	cerivastatin	18-30	C-X-C motif chemokine ligand 8	Homo sapiens	73-77
10694484-1	2000	We investigated the effect of cerivastatin on lipopolysaccharide (LPS)-induced intercellular adhesion molecule-1 (ICAM-1) expression in bovine aortic endothelial cells.	cerivastatin	30-42	intercellular adhesion molecule 1	Bos taurus	79-112
10694484-1	2000	We investigated the effect of cerivastatin on lipopolysaccharide (LPS)-induced intercellular adhesion molecule-1 (ICAM-1) expression in bovine aortic endothelial cells.	cerivastatin	30-42	intercellular adhesion molecule 1	Bos taurus	114-120
10694484-2	2000	Cerivastatin suppressed LPS-induced ICAM-1 mRNA expression.	cerivastatin	0-12	intercellular adhesion molecule 1	Bos taurus	36-42
10694484-6	2000	Although cerivastatin up-regulated endothelial nitric oxide synthase (eNOS), inhibition of nitric oxide (NO) synthesis by cotreatment with N(omega)-nitro-l-arginine methyl ester (L-NAME) exhibited no influence on the effect of cerivastatin.	cerivastatin	9-21	nitric oxide synthase 3	Bos taurus	35-68
10694484-7	2000	The present results indicate that cerivastatin prevents LPS-induced ICAM-1 expression in endothelial cells via inhibition of Rho activity.	cerivastatin	34-46	intercellular adhesion molecule 1	Bos taurus	68-74
10665838-7	1999	Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme.	cerivastatin	25-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-120
10898118-4	2000	Cerivastatin 0.8 mg reduced mean low density lipoprotein-cholesterol (LDL-C) by 41.8% compared with cerivastatin 0.4 mg (-35.6%, P < 0.0001) or placebo.	cerivastatin	0-12	component of oligomeric golgi complex 2	Homo sapiens	70-75
10898118-5	2000	In 90% of patients receiving cerivastatin 0.8 mg LDL-C was reduced by 23.9 -58.4% (6th - 95th percentile).	cerivastatin	29-41	component of oligomeric golgi complex 2	Homo sapiens	49-54
10898118-7	2000	In the sub-population meeting the NCEP criteria for pharmacological therapy for LDL-C reduction, 74.6% of patients, including the 59% with CHD, reached the goal with cerivastatin 0.8 mg. Cerivastatin 0.8 mg also reduced mean total cholesterol by 29.9%, apolipoprotein B by 33.2% and median triglycerides by 22.9% (all P < 0.0001).	cerivastatin	166-178	component of oligomeric golgi complex 2	Homo sapiens	80-85
10898118-7	2000	In the sub-population meeting the NCEP criteria for pharmacological therapy for LDL-C reduction, 74.6% of patients, including the 59% with CHD, reached the goal with cerivastatin 0.8 mg. Cerivastatin 0.8 mg also reduced mean total cholesterol by 29.9%, apolipoprotein B by 33.2% and median triglycerides by 22.9% (all P < 0.0001).	cerivastatin	187-199	component of oligomeric golgi complex 2	Homo sapiens	80-85
10898118-8	2000	Mean high density lipoprotein-cholesterol (HDL-C) and apolipoprotein A1 were elevated 8.7% (P < 0.0001) and 4.5% (P < 0.0001), respectively, by cerivastatin 0.8 mg.	cerivastatin	150-162	apolipoprotein A1	Homo sapiens	54-71
10898118-13	2000	Cerivastatin 0.8 mg is an effective and safe treatment for patients with primary hypercholesterolaemia who need aggressive LDL-C lowering in order to achieve NCEP-recommended levels.	cerivastatin	0-12	component of oligomeric golgi complex 2	Homo sapiens	123-128
11060668-0	2000	Cerivastatin: the low-dose HMG-COA reductase inhibitor.	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	27-44
11728245-1	2000	Cerivastatin is a synthetic and enantiomerically pure 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	54-111
11196073-9	2000	The presence of platelets increased the amount of tissue factor (55.3 +/- 7.3 pg/cells, P < 0.001) and cerivastatin reduced the expression of tissue factor in isolated monocytes, in the mixed cellular system, and in whole blood (19.6 +/- 4.1 pg/cells, P < 0.001).	cerivastatin	106-118	coagulation factor III, tissue factor	Homo sapiens	145-158
10215754-3	1999	RESULTS: Mibefradil inhibited, in a concentration-dependent fashion, the metabolism of the four statins (simvastatin, lovastatin, atorvastatin and cerivastatin) known to be substrates for CYP3A.	cerivastatin	147-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	188-193
10563066-5	1999	All four cerivastatin doses and simvastatin (20 mg) produced significantly greater falls than placebo (p < 0.0001) and the decrease in LDL-C was dose-dependent for cerivastatin.	cerivastatin	167-179	component of oligomeric golgi complex 2	Homo sapiens	138-143
10563066-10	1999	Mean fasting apolipoprotein A1 and lipoprotein A1 were increased and apolipoprotein B decreased by cerivastatin and simvastatin therapy.	cerivastatin	99-111	apolipoprotein B	Homo sapiens	69-85
10563066-15	1999	Cerivastatin, at doses of 0.1 mg and 0.2 mg daily, is considered to be of therapeutic value in the treatment of patients with primary hypercholesterolaemia, with 0.2 mg cerivastatin achieving reductions of LDL-C and total cholesterol similar to those achieved in the WOSCOP and CARE studies.	cerivastatin	0-12	component of oligomeric golgi complex 2	Homo sapiens	206-211
10563066-15	1999	Cerivastatin, at doses of 0.1 mg and 0.2 mg daily, is considered to be of therapeutic value in the treatment of patients with primary hypercholesterolaemia, with 0.2 mg cerivastatin achieving reductions of LDL-C and total cholesterol similar to those achieved in the WOSCOP and CARE studies.	cerivastatin	169-181	component of oligomeric golgi complex 2	Homo sapiens	206-211
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	cerivastatin	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	cerivastatin	60-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-136
11075617-6	1999	The effect of Cerivastatin on thrombin generation was evaluated too.	cerivastatin	14-26	coagulation factor II, thrombin	Homo sapiens	30-38
11075617-11	1999	Platelets directly influences this hypercoagulative state and Cerivastatin is able to reduce thrombin generation by way of a direct interaction with platelets.	cerivastatin	62-74	coagulation factor II, thrombin	Homo sapiens	93-101
10335757-1	1999	Cerivastatin is a third generation hydroxy-methyl-glutaryl-Co-enzyme A (HMG-CoA) reductase inhibitor proven to lower low-density lipoprotein (LDL) cholesterol 28% to 31% in patients with primary hypercholesterolemia when given at 0.3 mg/day.	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	35-90
9551706-1	1998	OBJECTIVE: Cerivastatin is a novel, synthetic, highly potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that effectively reduces serum cholesterol levels at very low doses.	cerivastatin	11-23	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	61-118
10096257-1	1999	OBJECTIVE: The mutual drug-drug interaction potential of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor cerivastatin and cyclosporine (INN, ciclosporin) in kidney transplant recipients receiving individual immunosuppressive treatment was evaluated with respect to pharmacokinetic behavior of either drug and tolerability of concomitant use.	cerivastatin	129-141	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	61-118
9793596-12	1998	In comparison, currently available HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin) lower LDL-C concentrations by approximately 20-40% and TG concentrations by approximately 10-30%.	cerivastatin	116-128	component of oligomeric golgi complex 2	Homo sapiens	136-141
9811154-1	1998	Cerivastatin, a novel, synthetic, and enantiomerically pure 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been administered, in clinical trials, to over 2700 patients with primary hypercholesterolemia, of whom over 1000 received treatment for periods of up to 1 year.	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	60-117
9663369-1	1998	Cerivastatin sodium, a synthetic and pure enantiomeric 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is considered effective in the treatment of mild-to-moderate primary hyper-cholesterolemia (total cholesterol < or = 220-259 mg/dL) at a daily dose of 0.15 mg. We compared the efficacy and tolerability of a dosage of 0.3 mg/d with those of a dosage of 0.15 mg/d in patients with severe primary hypercholesterolemia (serum total cholesterol > or = 260 mg/dL).	cerivastatin	0-19	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	55-112
9530546-1	1998	Cerivastatin is a synthetic HMG-CoA reductase inhibitor with high liver selectivity, which lowers plasma cholesterol levels by inhibiting endogenous cholesterol synthesis.	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	28-45
9530546-2	1998	In vitro, the affinity of cerivastatin for HMG-CoA reductase was higher than that of lovastatin, simvastatin and pravastatin.	cerivastatin	26-38	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	43-60
10193776-2	1999	The aim of this study was to examine whether cerivastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, affects the lesional composition of spontaneously developed atherosclerosis due to hypercholesterolaemia and delays progression of the lesions.	cerivastatin	45-64	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	85-142
10193776-4	1999	We administered cerivastatin to 2-month-old WHHL rabbits, a low-density lipoprotein receptor-deficient animal model, at a dose of 0.6 mg kg(-1) day(-1) for 32 weeks.	cerivastatin	16-28	low-density lipoprotein receptor	Oryctolagus cuniculus	60-92
11563401-7	1999	Of all the HMG CoA reductase inhibitors, cerivastatin is the most potent inhibitor of vascular smooth muscle proliferation.	cerivastatin	41-53	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	11-28
11563406-1	1999	The influence of renal impairment on the clearance of the new HMG-CoA reductase inhibitor cerivastatin was evaluated.	cerivastatin	90-102	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	62-79
10027660-1	1999	OBJECTIVE: To determine the effects of itraconazole, a potent inhibitor of CYP3A4, on the pharmacokinetics of cerivastatin, a competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.	cerivastatin	110-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
10027660-1	1999	OBJECTIVE: To determine the effects of itraconazole, a potent inhibitor of CYP3A4, on the pharmacokinetics of cerivastatin, a competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.	cerivastatin	110-122	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	138-195
10027660-11	1999	Inhibition of the CYP3A4-mediated M-1 metabolic pathway leads to elevated serum concentrations of cerivastatin, cerivastatin lactone and metabolite M-23, resulting in increased concentrations of active HMG-CoA reductase inhibitors.	cerivastatin	98-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
9737641-1	1998	Cerivastatin is a new but structurally distinct 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor ("statin").	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	48-105
9737642-1	1998	Cerivastatin, a new, entirely synthetic, and enantiomerically pure 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is pharmacologically potent and hepatically selective, with an uncomplicated pharmacokinetic profile.	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	67-124
9737643-6	1998	Cerivastatin also significantly decreased total cholesterol, triglycerides, and apolipoprotein B, and significantly increased high-density lipoprotein (HDL) cholesterol.	cerivastatin	0-12	apolipoprotein B	Homo sapiens	80-96
9737645-1	1998	Cerivastatin, a novel, synthetic, and enantiomerically pure 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been administered, in clinical trials, to >2,700 patients with primary hypercholesterolemia, of whom > 1,000 received treatment for periods of up to 1 year.	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	60-117
9551706-16	1998	The pharmacokinetic data for the major metabolites suggest that the M1 metabolic pathway is more sensitive to CYP3A4 inhibition than the parallel M23 pathway, supporting recent in vitro findings that further cytochrome P450 isozymes are differently involved in the metabolic pathways of cerivastatin.	cerivastatin	287-299	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
9740537-7	1998	Unlike other drugs of its class, cerivastatin has a dual metabolic pathway, with the involvement of more than one CYP isozyme.	cerivastatin	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-117
9358961-0	1997	Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium (CAS 143201-11-0, BAY w 6228), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in dogs.	cerivastatin	80-99	low density lipoprotein receptor	Homo sapiens	64-76
9395280-1	1997	The pyridine derivative cerivastatin is a new entirely synthetic and enantiomerically pure inhibitor of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase.	cerivastatin	24-36	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	104-154
9358961-0	1997	Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium (CAS 143201-11-0, BAY w 6228), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in dogs.	cerivastatin	80-99	3-hydroxy-3-methylglutaryl-CoA reductase	Canis lupus familiaris	150-197
9358961-1	1997	The effects of cerivastatin sodium (BAY w 6228), a new type of inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on plasma cholesterol concentrations and the induction of hepatic LDL receptors were investigated with beagle dogs and Hep G2 cells.	cerivastatin	15-34	3-hydroxy-3-methylglutaryl-CoA reductase	Canis lupus familiaris	76-133
9358961-2	1997	Oral administration of cerivastatin (0.01, 0.03, and 0.1 mg/kg per day) for 3 weeks reduced plasma total and very low-density lipoprotein plus low-density lipoprotein (VLDL + LDL) cholesterol concentrations and increased hepatic LDL receptor binding activity in dogs.	cerivastatin	23-35	low density lipoprotein receptor	Homo sapiens	229-241
9358961-5	1997	Binding activity of the LDL receptor, as well as receptor mRNA and protein concentrations, were increased in a dose-dependent manner (0.01-1.0 microM) by exposure of Hep G2 cells to cerivastatin.	cerivastatin	182-194	low density lipoprotein receptor	Homo sapiens	24-36
9358961-6	1997	The results suggest that cerivastatin reduces plasma cholesterol concentrations by increasing hepatic LDL receptor expression.	cerivastatin	25-37	low density lipoprotein receptor	Homo sapiens	102-114
9050782-1	1997	To determine the in vivo activity of BAYw6228 (BAYw), a newly developed 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, we examined its effect on balloon catheterization-induced carotid arterial intimal thickening in Japanese white rabbits.	cerivastatin	37-45	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	72-122
9208341-1	1997	The possible influence of the bile acid sequestering agent cholestyramine, a basic comedication in hypercholesterolemic patients, on the pharmacokinetics of the new HMG-CoA reductase inhibitor cerivastatin was investigated.	cerivastatin	193-205	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	165-182
9134232-2	1997	The aim of this study was to determine whether BAYw6228 (BAYw), a newly developed 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, could suppress an atherogenic process such as intimal thickening by a mechanism other than lowering the level of serum cholesterol.	cerivastatin	47-55	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	82-132
9134232-2	1997	The aim of this study was to determine whether BAYw6228 (BAYw), a newly developed 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor, could suppress an atherogenic process such as intimal thickening by a mechanism other than lowering the level of serum cholesterol.	cerivastatin	47-51	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	82-132
9172950-10	1997	Upon incubation of cerivastatin with human liver microsomes in the presence of the specific CYP 3A inhibitor TAO, both hydroxylation and demethylation were considerably reduced.	cerivastatin	19-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
9172950-11	1997	This indicates that CYP 3A enzymes play a major role in cerivastatin metabolism.	cerivastatin	56-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
10684437-10	1997	CONCLUSION: Cerivastatin is a novel, highly potent, well-tolerated HMG-CoA reductase inhibitor that produces low-density lipoprotein cholesterol reductions of approximately 30% when administered at 0.2 mg once a day in the evenings.	cerivastatin	12-24	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	67-84
8817647-0	1996	Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes.	cerivastatin	46-58	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	18-35
8561503-3	1996	We found that administration of inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase such as lovastatin, pravastatin, fluvastatin, and rivastatin resulted in increased hepatic LDL receptor mRNA levels.	cerivastatin	144-154	low density lipoprotein receptor	Rattus norvegicus	185-197
10684437-3	1997	Cerivastatin is the most potent HMG-CoA reductase inhibitor currently under study in the United States.	cerivastatin	0-12	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	32-49
8817647-0	1996	Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes.	cerivastatin	60-70	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	18-35
8817647-1	1996	The major relation existing between cell growth, migration and cholesterol homeostasis prompted us to investigate the effect of the new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor cerivastatin (BAY W 6228) on these cellular events.	cerivastatin	204-216	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	136-193
34830364-5	2021	Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6.	cerivastatin	90-102	tumor necrosis factor	Mus musculus	272-293
34830364-5	2021	Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6.	cerivastatin	90-102	tumor necrosis factor	Mus musculus	295-298
34830364-5	2021	Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6.	cerivastatin	90-102	interleukin 1 alpha	Mus musculus	301-323
34830364-5	2021	Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6.	cerivastatin	90-102	interleukin 6	Mus musculus	329-332